molecule_chembl_id,canonical_smiles,assay_description,assay_type,target_organism,target_pref_name,bioactivity_class,standard_value,target_organism_canonical_smiles,target_organism_isomeric_smiles,"bioactivity_class_labels (0-inactive, 1-active, 2-intermediate)",MW,LogP,NumHDonors,NumHAcceptors
CHEMBL204499,NC(=O)c1ncn([C@@H]2C=C(CO)[C@@H](O)[C@H]2O)n1,Cytotoxicity against SARS coronavirus,A,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,240.219,-2.4278,4,7
CHEMBL203308,NC(=O)c1cn([C@@H]2C=C(CO)[C@@H](O)[C@H]2O)nn1,Cytotoxicity against SARS coronavirus,A,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,240.219,-2.4278,4,7
CHEMBL381539,NC(=O)c1cn([C@@H]2C=C(CO)[C@@H](O)[C@H]2O)cn1,Cytotoxicity against SARS coronavirus,A,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,239.231,-1.8228,4,6
CHEMBL225045,Nc1nc(O)c2[nH]cc([C@@H]3C=C(CO)[C@@H](O)[C@H]3O)c2n1,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,278.268,-1.0166,6,7
CHEMBL224363,O=c1[nH]cc([C@@H]2C=C(CO)[C@@H](O)[C@H]2O)c(=O)[nH]1,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,240.215,-2.1991,5,5
CHEMBL225046,Nc1nc(=O)c([C@@H]2C=C(CO)[C@@H](O)[C@H]2O)c[nH]1,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,239.231,-1.9102,5,6
CHEMBL397974,OC[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)[C@H](O)[C@@H]1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,48700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,286.675,-0.9088,3,8
CHEMBL245019,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,13500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,259.218,-2.7009,5,8
CHEMBL1643,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,82000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,244.207,-3.0115,4,8
CHEMBL243757,OCC1C(COCc2ccccc2)CC1n1cnc2c(Cl)ncnc21,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,14500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,358.829,2.866,1,6
CHEMBL388704,OCC1CC(n2cnc3c(Cl)ncnc32)C1CO,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,268.704,0.6415,2,6
CHEMBL244381,OCC(CCn1cnc2c(Cl)ncnc21)COCc1ccccc1,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,346.818,2.6951,1,6
CHEMBL388932,OCC(CO)CCn1cnc2c(Cl)ncnc21,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,256.693,0.4706,2,6
CHEMBL244380,OC[C@@H]1C[C@@H](O)[C@H](n2cnc3c(Cl)ncnc32)O1,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,270.676,0.1204,2,7
CHEMBL244379,OC[C@H]1O[C@@H](n2cnc3c(Cl)ncnc32)C[C@@H]1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,270.676,0.1204,2,7
CHEMBL244169,Nc1nc(Cl)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2n1,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,301.69,-1.3266,4,9
CHEMBL388931,CSc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.324,-0.8403,3,9
CHEMBL244168,COc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,282.256,-1.5536,3,9
CHEMBL245013,O[C@@H]1[C@@H](COCc2ccccc2)O[C@@H](n2cnc3c(Cl)ncnc32)[C@@H]1O,Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay,F,SARS coronavirus,SARS coronavirus,inactive,108000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,376.8,1.3157,2,8
CHEMBL235873,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,659.781,0.8706,6,9
CHEMBL397154,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,625.764,0.674,6,9
CHEMBL238217,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC=C(C)C)CC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,75000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,636.787,2.0748,5,9
CHEMBL196635,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC=C(C)C)CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,70000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,558.676,2.79942,3,8
CHEMBL194398,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C)Cc1ccccc1,Antiviral activity against SARS coronavirus,F,SARS coronavirus,SARS coronavirus,inactive,45000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,580.682,2.68582,3,8
CHEMBL490210,CC(=O)N1Cc2ccccc2C[C@H]1C(=O)Oc1cncc(Cl)c1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,140,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,330.771,2.6138,0,4
CHEMBL490209,CC(C)(C)OC(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)Oc3cncc(Cl)c3)C(C)(C)S[C@H]12,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,427.91,2.596,1,7
CHEMBL490822,O=C(Oc1cncc(Cl)c1)c1cccc2cc[nH]c12,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,80,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,272.691,3.4355,1,3
CHEMBL490820,O=C(Oc1cncc(Cl)c1)c1cccc2[nH]ccc12,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,30,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,272.691,3.4355,1,3
CHEMBL496179,O=C(Oc1cncc(Cl)c1)c1ccc2cc[nH]c2c1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,230,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,272.691,3.4355,1,3
CHEMBL496316,O=C(Oc1cncc(Cl)c1)c1ccc2c(ccn2S(=O)(=O)c2cccc([N+](=O)[O-])c2)c1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,89,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,457.851,4.0541,0,8
CHEMBL497351,Cc1ccc(S(=O)(=O)n2ccc3cc(C(=O)Oc4cncc(Cl)c4)ccc32)cc1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,370,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,426.881,4.45432,0,6
CHEMBL497143,CC(=O)n1ccc2cc(C(=O)Oc3cncc(Cl)c3)ccc21,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,314.728,3.569,0,5
CHEMBL510559,O=C(Oc1cncc(Cl)c1)c1ccc2[nH]ccc2c1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,310,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,272.691,3.4355,1,3
CHEMBL497141,O=C(On1nnc2ccccc21)c1ccc2[nH]ccc2c1,Antiviral activity against SARS-CoV Urbani in african green monkey Vero E6 cells assessed as cell viability after 48 hrs,F,SARS coronavirus,SARS coronavirus,active,200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,278.271,2.1816,1,5
CHEMBL185698,O=C1C(=O)N(CC2COc3ccccc3O2)c2ccc(I)cc21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease) at 20 uM,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,13500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,421.19,2.6605,0,4
CHEMBL426082,O=C1C(=O)N(Cc2cc3ccccc3s2)c2ccccc21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,13110,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,293.347,3.6308,0,3
CHEMBL365134,O=C1C(=O)N(Cc2cc3ccccc3s2)c2c(Br)cccc21,In vitro inhibitory concentration SARS coronavirus main protease (SARS CoV 3C-like protease) ,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,980,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,372.243,4.3933,0,3
CHEMBL190743,O=C1C(=O)N(Cc2cc3ccccc3s2)c2ccc(I)cc21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,950,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,419.243,4.2354,0,3
CHEMBL365469,O=C1C(=O)N(Cc2cc3ccccc3s2)c2cccc(Cl)c21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,11200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,327.792,4.2842,0,3
CHEMBL188983,O=C1C(=O)N(C/C=C/c2cc3ccccc3s2)c2ccc(I)cc21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,23500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,445.281,4.7486,0,3
CHEMBL191575,O=C(Nc1ccc(Cl)cc1)c1ccc(CN2C(=O)C(=O)c3cc(I)ccc32)s1,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,12570,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,522.751,4.9879,1,4
CHEMBL370923,O=C1C(=O)N(Cc2ccc(C(=O)N3CCCCC3)s2)c2ccc(I)cc21,In vitro inhibitory concentration against SARS coronavirus main protease (SARS CoV 3C-like protease),B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,17500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,480.327,3.7083,0,4
CHEMBL194398,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C)Cc1ccccc1,Inhibitory concentration required for antiviral activity against SARS-CoV 3CLpro protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,45000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,580.682,2.68582,3,8
CHEMBL196635,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC=C(C)C)CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C,Inhibitory concentration required for antiviral activity against SARS-CoV 3CLpro protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,70000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,558.676,2.79942,3,8
CHEMBL209287,CCCCN1C(=O)C(=O)c2cc(I)ccc21,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,66000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,329.137,2.6206,0,2
CHEMBL358279,NC(=O)c1ccc2c(c1)C(=O)C(=O)N2Cc1ccc2ccccc2c1,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,370,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,330.343,2.6682,1,3
CHEMBL348660,NC(=O)c1ccc2c(c1)C(=O)C(=O)N2Cc1ccccc1,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,12500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,280.283,1.515,1,3
CHEMBL379727,CCCCN1C(=O)C(=O)c2cc(C(N)=O)ccc21,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,19000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,246.266,1.1149,1,3
CHEMBL210525,CCCN1C(=O)C(=O)c2cc(C(N)=O)ccc21,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,232.239,0.7248,1,3
CHEMBL148483,CN1C(=O)C(=O)c2cc(C(N)=O)ccc21,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,71000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,204.185,-0.0554,1,3
CHEMBL118596,O=C1C(=O)N(Cc2ccccc2)c2ccc(I)cc21,Inhibition of SARS CoV 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,363.154,3.0207,0,2
CHEMBL208732,O=C(CSc1nccc(-c2csc(-c3ccccc3)n2)n1)Nc1cc(Cl)cc(Cl)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.31E+14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,473.41,6.3047,1,6
CHEMBL210146,COc1cccc(-c2nc(SCC(=O)Nc3ccc([N+](=O)[O-])cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.31E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,437.437,3.36848,2,9
CHEMBL210146,COc1cccc(-c2nc(SCC(=O)Nc3ccc([N+](=O)[O-])cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,437.437,3.36848,2,9
CHEMBL207458,CCOC(=O)c1cnc(SCC(=O)Nc2ccc([N+](=O)[O-])cc2)nc1N,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.98E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,377.382,1.8745,2,9
CHEMBL207458,CCOC(=O)c1cnc(SCC(=O)Nc2ccc([N+](=O)[O-])cc2)nc1N,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,250000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,377.382,1.8745,2,9
CHEMBL207484,COC(OC)c1cc(O)nc(SCC(=O)Nc2ccc(C(F)(F)F)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,4.90E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,403.382,3.2232,2,7
CHEMBL207484,COC(OC)c1cc(O)nc(SCC(=O)Nc2ccc(C(F)(F)F)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,403.382,3.2232,2,7
CHEMBL207207,Cc1cc(O)nc(SCC(=O)Nc2cc(Cl)ccc2Oc2ccccc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1.00E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,401.875,4.66712,2,6
CHEMBL207207,Cc1cc(O)nc(SCC(=O)Nc2cc(Cl)ccc2Oc2ccccc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,401.875,4.66712,2,6
CHEMBL210487,CCC(Sc1nc(O)c(C#N)c(-c2cccc(OC)c2)n1)C(=O)Nc1ccc(C(C)=O)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1.66E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,462.531,4.44148,2,8
CHEMBL210487,CCC(Sc1nc(O)c(C#N)c(-c2cccc(OC)c2)n1)C(=O)Nc1ccc(C(C)=O)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,60000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,462.531,4.44148,2,8
CHEMBL380470,COc1ccc(NC(=O)CSc2nc(O)cc(-c3ccccc3)n2)cc1OC,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.19E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,397.456,3.5972,2,7
CHEMBL380470,COc1ccc(NC(=O)CSc2nc(O)cc(-c3ccccc3)n2)cc1OC,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,45000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,397.456,3.5972,2,7
CHEMBL210612,CC(C)c1ccc(NC(=O)CSc2nccc(-c3cccs3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.45E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,369.515,5.0593,1,5
CHEMBL210612,CC(C)c1ccc(NC(=O)CSc2nccc(-c3cccs3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,40000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,369.515,5.0593,1,5
CHEMBL209667,O=C(CSc1nccc(-c2cc(-c3ccccc3Cl)no2)n1)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,6.61E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,457.342,5.8362,1,6
CHEMBL209667,O=C(CSc1nccc(-c2cc(-c3ccccc3Cl)no2)n1)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,457.342,5.8362,1,6
CHEMBL210097,O=C(CSc1nccc(-c2cc(-c3ccc(Cl)cc3Cl)no2)n1)Nc1ccc(C(F)(F)F)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,6.61E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,525.339,6.855,1,6
CHEMBL210097,O=C(CSc1nccc(-c2cc(-c3ccc(Cl)cc3Cl)no2)n1)Nc1ccc(C(F)(F)F)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,525.339,6.855,1,6
CHEMBL378674,CSc1sc(-c2nc(C)cs2)c(C)c1-c1ccnc(SCC(=O)Nc2ccccc2Cl)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,8.32E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,519.142,7.05154,1,8
CHEMBL378674,CSc1sc(-c2nc(C)cs2)c(C)c1-c1ccnc(SCC(=O)Nc2ccccc2Cl)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,12000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,519.142,7.05154,1,8
CHEMBL210216,Cc1nc(SCC(=O)Nc2ccc([N+](=O)[O-])cc2)nc(O)c1C,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1.00E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,334.357,2.43804,2,7
CHEMBL210216,Cc1nc(SCC(=O)Nc2ccc([N+](=O)[O-])cc2)nc(O)c1C,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1000000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,334.357,2.43804,2,7
CHEMBL210195,Cc1cc(C(F)(F)F)nc(SCC(=O)Nc2ccc(Cl)cc2F)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.00E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,379.766,4.32712,1,4
CHEMBL210195,Cc1cc(C(F)(F)F)nc(SCC(=O)Nc2ccc(Cl)cc2F)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,500000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,379.766,4.32712,1,4
CHEMBL210437,COc1ccc(-c2ccnc(SCC(=O)Nc3ccc(C(C)C)cc3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.45E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,393.512,5.0064,1,5
CHEMBL210437,COc1ccc(-c2ccnc(SCC(=O)Nc3ccc(C(C)C)cc3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,400000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,393.512,5.0064,1,5
CHEMBL378677,CC(C)(C)c1ccc(NC(=O)CSc2nc(O)c(C#N)c(C3CCCCC3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.82E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,424.57,5.12988,2,6
CHEMBL378677,CC(C)(C)c1ccc(NC(=O)CSc2nc(O)c(C#N)c(C3CCCCC3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,350000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,424.57,5.12988,2,6
CHEMBL210972,CC(Sc1nc(O)c(C#N)c(-c2ccccc2)n1)C(=O)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.31E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,410.886,4.49358,2,6
CHEMBL210972,CC(Sc1nc(O)c(C#N)c(-c2ccccc2)n1)C(=O)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,410.886,4.49358,2,6
CHEMBL210145,CCOc1ccc(N2C(=O)CC(Sc3nc(C)cc(C)n3)C2=O)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.31E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,357.435,2.91634,0,6
CHEMBL210145,CCOc1ccc(N2C(=O)CC(Sc3nc(C)cc(C)n3)C2=O)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,357.435,2.91634,0,6
CHEMBL377225,N#Cc1c(O)nc(SCC(=O)Nc2cccc(C(F)(F)F)c2)nc1-c1ccccc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,4.90E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,430.411,4.47048,2,6
CHEMBL377225,N#Cc1c(O)nc(SCC(=O)Nc2cccc(C(F)(F)F)c2)nc1-c1ccccc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,430.411,4.47048,2,6
CHEMBL210823,CCCCc1ccc(NC(=O)CSc2nc(O)c(C#N)c(C3CCCCC3)n2)c(C)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,4.90E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,438.597,5.4834,2,6
CHEMBL210823,CCCCc1ccc(NC(=O)CSc2nc(O)c(C#N)c(C3CCCCC3)n2)c(C)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,438.597,5.4834,2,6
CHEMBL207381,CC(C)c1ccc(NC(=O)CSc2nccc(-c3csc(COc4ccccc4Cl)n3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,4.90E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,511.072,6.6867,1,7
CHEMBL207381,CC(C)c1ccc(NC(=O)CSc2nccc(-c3csc(COc4ccccc4Cl)n3)n2)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,511.072,6.6867,1,7
CHEMBL210511,Cc1cc(O)nc(SCC(=O)Nc2ccc(Oc3ccc(Cl)cc3)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,4.90E+12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,401.875,4.66712,2,6
CHEMBL210511,Cc1cc(O)nc(SCC(=O)Nc2ccc(Oc3ccc(Cl)cc3)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,401.875,4.66712,2,6
CHEMBL210632,COc1cccc(-c2nc(SCC(=O)Nc3ccc(C(C)=O)cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1.66E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,434.477,3.66288,2,8
CHEMBL210632,COc1cccc(-c2nc(SCC(=O)Nc3ccc(C(C)=O)cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,60000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,434.477,3.66288,2,8
CHEMBL210497,COc1cccc(-c2nc(SCC(=O)Nc3ccc(S(N)(=O)=O)cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,2.45E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,471.52,2.10768,3,9
CHEMBL210497,COc1cccc(-c2nc(SCC(=O)Nc3ccc(S(N)(=O)=O)cc3)nc(O)c2C#N)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,40000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,471.52,2.10768,3,9
CHEMBL208584,CCCc1cc(O)nc(SCC(=O)Nc2ccc(Cl)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,3.31E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,337.832,3.5189,2,5
CHEMBL208584,CCCc1cc(O)nc(SCC(=O)Nc2ccc(Cl)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,30000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,337.832,3.5189,2,5
CHEMBL208763,O=C(CSc1nccc(-c2cc(-c3ccccc3)no2)n1)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,6.61E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,422.897,5.1828,1,6
CHEMBL208763,O=C(CSc1nccc(-c2cc(-c3ccccc3)no2)n1)Nc1ccc(Cl)cc1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,422.897,5.1828,1,6
CHEMBL209227,Cc1nc(-c2nc(-c3ccnc(SCC(=O)Nc4ccc(Cl)cc4)n3)cs2)cs1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,7.08E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,460.009,5.41622,1,8
CHEMBL209227,Cc1nc(-c2nc(-c3ccnc(SCC(=O)Nc4ccc(Cl)cc4)n3)cs2)cs1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,14000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,460.009,5.41622,1,8
CHEMBL210092,CSc1sc(-c2nc(C)cs2)c(C)c1-c1ccnc(SCC(=O)Nc2ccc(Cl)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,8.91E+13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,519.142,7.05154,1,8
CHEMBL210092,CSc1sc(-c2nc(C)cs2)c(C)c1-c1ccnc(SCC(=O)Nc2ccc(Cl)cc2)n1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,11000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,519.142,7.05154,1,8
CHEMBL377150,Cn1nc(-c2ccc(-c3ccnc(SCC(=O)Nc4ccc(Cl)cc4)n3)s2)cc1C(F)(F)F,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,1.00E+14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,509.966,6.0086,1,7
CHEMBL377150,Cn1nc(-c2ccc(-c3ccnc(SCC(=O)Nc4ccc(Cl)cc4)n3)s2)cc1C(F)(F)F,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,509.966,6.0086,1,7
CHEMBL212454,O=C(Oc1ccc(S(=O)(=O)c2ccc(OC(=O)C(Cl)=C(Cl)Cl)cc2)cc1)C(Cl)=C(Cl)Cl,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,565.041,6.1012,0,6
CHEMBL380403,O=[N+]([O-])c1cc(C(F)(F)F)ccc1S(=O)(=O)c1ccc(Cl)cc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,12000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,365.716,4.0998,0,4
CHEMBL212504,Cc1nc(S(=O)(=O)c2ccccc2)c(C#N)c(C)c1[N+](=O)[O-],Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,13000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,317.326,2.31112,0,6
CHEMBL211969,Cc1ccc(S(=O)(=O)c2nc(C)c([N+](=O)[O-])c(C)c2C#N)cc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,13000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.353,2.61954,0,6
CHEMBL384739,O=[N+]([O-])c1ccc(S(=O)(=O)c2ccc(Cl)cc2)[n+]([O-])c1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,314.706,1.7144,0,5
CHEMBL215732,CCOC(=O)/C(C#N)=C/Nc1ccc(S(=O)(=O)c2ccc(/N=C/C(C#N)=C(\O)OCC)cc2)cc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,16000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,494.529,3.93386,2,10
CHEMBL212240,O=C(O)c1ccc(S(=O)(=O)c2cc(Br)c(O)c(Br)c2)cc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,16000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,436.077,3.4482,2,4
CHEMBL377253,CC(=O)c1ccccc1S(=O)(=O)c1ccccc1C(=O)O,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,16000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,304.323,2.4202,1,4
CHEMBL215397,O=[N+]([O-])c1ccc(S(=O)(=O)c2ccc([N+](=O)[O-])cc2)cc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,308.271,2.3358,0,6
CHEMBL378342,CCOC(=O)C(=CNc1ccc(S(=O)(=O)c2ccc(/N=C/C(C(=O)OCC)=C(\O)OCC)cc2)cc1)C(=O)OCC,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,32000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,588.635,4.0129,2,12
CHEMBL212190,Cc1oc(C(C)(C)C)cc1-c1cc(NS(=O)(=O)c2cccs2)[nH]n1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,365.48,4.13792,2,5
CHEMBL378700,CSc1[nH]nc(NC(=O)c2cccs2)c1S(=O)(=O)c1ccccc1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,379.488,3.2782,2,6
CHEMBL212019,CC1(C)CC(=O)c2c(NCc3ccco3)sc(C#N)c2C1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,16000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,300.383,3.97998,1,5
CHEMBL212399,CSc1nn(-c2c([N+](=O)[O-])c(C)nn2C)c(-c2cccs2)c1C#N,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,18000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,360.424,3.1445,0,9
CHEMBL215733,O=S(=O)(Cc1[nH]c(-c2ccc(Cl)s2)c[s+]1)c1cccs1.[Br-],Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,18000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,442.834,1.7786,1,4
CHEMBL375130,Cc1nn(C)c(NCc2ccc(-c3cccs3)s2)c1[N+](=O)[O-],Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,20000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,334.426,4.03882,1,7
CHEMBL214372,O=C(Cc1nccs1)c1nccs1,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,40000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,210.283,2.025,0,5
CHEMBL212218,Cc1cc(S(=O)(=O)c2c([N+](=O)[O-])cc(C(F)(F)F)cc2[N+](=O)[O-])c(Cl)cc1Cl,Inhibition of SARS coronavirus main protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,459.185,4.96982,0,6
CHEMBL222840,O=C(Oc1cncc(Cl)c1)c1ccco1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,60,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,223.615,2.5472,0,4
CHEMBL222769,O=C(Oc1cncc(Cl)c1)c1ccc(-c2ccc(Cl)cc2)o1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,63,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.158,4.8676,0,4
CHEMBL222735,COc1cccc(C(=O)Oc2cncc(Cl)c2)c1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,340,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,263.68,2.9628,0,4
CHEMBL222628,O=C(Oc1cncc(Cl)c1)c1cscn1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,270,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,240.671,2.4107,0,5
CHEMBL222893,O=C(Oc1cncc(Cl)c1)c1cc2ccccc2s1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,95,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,289.743,4.1689,0,4
CHEMBL225515,O=C(Oc1cncc(Cl)c1)c1cc2ccccc2[nH]1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,65,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,272.691,3.4355,1,3
CHEMBL222234,O=C(Oc1cncc(Br)c1)c1ccco1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,50,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,268.066,2.6563,0,4
CHEMBL426898,O=C(Oc1cncc(Cl)c1)c1cc2ccccc2o1,Inhibition of SARS coronavirus 3C-like protease,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,170,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,273.675,3.7004,0,4
CHEMBL187266,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,89100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,294.35,4.24792,0,3
CHEMBL215254,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)CO,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,24800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,310.349,3.22032,1,4
CHEMBL2146517,COC(=O)[C@@]1(C)CCCc2c1ccc1c2C(=O)C(=O)c2c(C)coc2-1,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,21100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,338.359,3.40102,0,5
CHEMBL187460,C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,226700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.366,3.4433,0,3
CHEMBL363535,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,38700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,276.291,4.09564,0,3
CHEMBL227075,Cc1cccc2c3c(ccc12)C1=C(C(=O)C3=O)[C@@H](C)CO1,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,14400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,278.307,3.29102,0,3
CHEMBL45830,CC(C)C1=Cc2ccc3c(c2C(=O)C1=O)CCCC3(C)C,Inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate after 60 mins by FRET analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,21100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,282.383,4.1053,0,2
CHEMBL215254,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)CO,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 30 mins by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,310.349,3.22032,1,4
CHEMBL187460,C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 30 mins by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,296.366,3.4433,0,3
CHEMBL45830,CC(C)C1=Cc2ccc3c(c2C(=O)C1=O)CCCC3(C)C,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate preincubated for 30 mins by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,30000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,282.383,4.1053,0,2
CHEMBL215254,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)CO,Inhibition of SARS-CoV PLpro deubiququitination expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,52000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,310.349,3.22032,1,4
CHEMBL187460,C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV PLpro deubiququitination expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,87600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.366,3.4433,0,3
CHEMBL363535,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,Inhibition of SARS-CoV PLpro deubiququitination expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,active,700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,276.291,4.09564,0,3
CHEMBL45830,CC(C)C1=Cc2ccc3c(c2C(=O)C1=O)CCCC3(C)C,Inhibition of SARS-CoV PLpro deubiququitination expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence analysis,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,60200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,282.383,4.1053,0,2
CHEMBL187266,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,17100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,294.35,4.24792,0,3
CHEMBL215254,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCCC2(C)CO,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,18000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,310.349,3.22032,1,4
CHEMBL2146517,COC(=O)[C@@]1(C)CCCc2c1ccc1c2C(=O)C(=O)c2c(C)coc2-1,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,338.359,3.40102,0,5
CHEMBL187460,C[C@H]1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.366,3.4433,0,3
CHEMBL363535,Cc1coc2c1C(=O)C(=O)c1c-2ccc2c(C)cccc12,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,11500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,276.291,4.09564,0,3
CHEMBL227075,Cc1cccc2c3c(ccc12)C1=C(C(=O)C3=O)[C@@H](C)CO1,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,10700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,278.307,3.29102,0,3
CHEMBL45830,CC(C)C1=Cc2ccc3c(c2C(=O)C1=O)CCCC3(C)C,Inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence assay,B,SARS coronavirus,SARS coronavirus 3C-like proteinase,inactive,78900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,282.383,4.1053,0,2
CHEMBL4471536,CC(=O)c1c(NC(C)C)[nH]c2c(C(F)(F)F)cc(Cl)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,770,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,346.736,4.2232,2,3
CHEMBL4472908,CC(=O)c1c(NC(C)C)[nH]c2c(C(C)C)cccc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,286.375,3.6744,2,3
CHEMBL4580358,CC(=O)c1c(NC(C)C)[nH]c2c(C)cc(C)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,272.348,3.16784,2,3
CHEMBL4531009,CC(C)Nc1[nH]c2c(C(F)(F)F)cc(Cl)cc2c(=O)c1C(=O)c1ccccc1,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,408.807,5.2516,2,3
CHEMBL4554138,CC(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(C(F)(F)F)cc(Cl)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,150,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,416.733,5.4247,2,3
CHEMBL4530008,CC(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(F)cc(Cl)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,980,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,366.726,4.545,2,3
CHEMBL4565616,CC(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(Cl)cc(Cl)c(Cl)c2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,290,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,417.626,5.7127,2,3
CHEMBL4460922,CC(=O)c1c(N2CCCCC2)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,306.312,2.9992,1,3
CHEMBL4469302,CC(=O)c1c(N2CCOCC2)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,308.284,1.8455,1,4
CHEMBL4451470,CCCCNc1[nH]c2c(F)cc(F)cc2c(=O)c1C(C)=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,294.301,3.2209,2,3
CHEMBL4452847,CC(=O)c1c(NCc2ccc(F)cc2)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,17600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,346.308,3.7601,2,3
CHEMBL4578865,COc1ccc(CNc2[nH]c3c(F)cc(F)cc3c(=O)c2C(C)=O)cc1,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,358.344,3.6296,2,4
CHEMBL4561863,COc1cccc(Nc2[nH]c3c(F)cc(F)cc3c(=O)c2C(C)=O)c1,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,344.317,3.7611,2,4
CHEMBL4455226,COc1ccc(Nc2[nH]c3c(F)cc(F)cc3c(=O)c2C(C)=O)cc1,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,344.317,3.7611,2,4
CHEMBL4444752,CC(=O)c1c(Nc2ccc(F)c(F)c2F)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,530,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,368.261,4.1698,2,3
CHEMBL4526734,CC(C)C(=O)c1c(Nc2ccc(F)c(F)c2F)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,86,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,396.315,4.8059,2,3
CHEMBL4463570,CC(C)C(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(F)cc(F)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,790,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,378.325,4.6668,2,3
CHEMBL4572255,CC(C)C(=O)c1c(Nc2ccc(F)c(F)c2F)[nH]c2c(Cl)cc(Cl)c(Cl)c2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,463.67,6.4879,2,3
CHEMBL4558866,CC(C)C(=O)c1c(Nc2ccc(F)c(F)c2F)[nH]c2c(Cl)ccc(Cl)c2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,166,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,429.225,5.8345,2,3
CHEMBL4459172,CC(C)C(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(Cl)cc(Cl)c(Cl)c2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,129,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,445.68,6.3488,2,3
CHEMBL4545243,CC(C)C(=O)c1c(Nc2ccc(F)cc2F)[nH]c2c(C(F)(F)F)cc(Cl)cc2c1=O,Antiviral activity against MERS-CoV KOR/KNIH/002_05_2015 infected in African green monkey Vero cells expressing viral spike protein by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,130,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.787,6.0608,2,3
CHEMBL4798318,CCCCN(CCCC)c1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,400.929,6.5725,1,4
CHEMBL4784569,NC(=O)c1cccc(CNc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,421.863,4.8769,3,5
CHEMBL4779105,N#Cc1cccc(C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,417.831,5.28988,2,5
CHEMBL3814257,CC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,330.75,4.1243,2,4
CHEMBL4744542,Fc1ccc(Nc2ncnc3ccc(NC4CCCCC4)cc23)cc1Cl,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,370.859,5.9105,2,4
CHEMBL4755225,COc1cccc(CNc2ccc3ncnc(Nc4cccc(C(C)=O)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,398.466,5.1967,2,6
CHEMBL4743746,COc1cccc(CNc2ccc3ncnc(Nc4ccc(C#N)cc4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,381.439,4.86578,2,6
CHEMBL4749703,COc1cccc(CNc2ccc3ncnc(Nc4ccc(F)cc4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,22700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,374.419,5.1332,2,5
CHEMBL4781730,COc1cccc(CNc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,390.874,5.6475,2,5
CHEMBL4781940,N#Cc1cccc(CNc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,157,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,403.848,5.64968,2,5
CHEMBL4792429,N#Cc1ccccc1CNc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,403.848,5.64968,2,5
CHEMBL4783296,N#Cc1ccccc1CNc1ccc2ncnc(Nc3ccc(C(F)(F)F)cc3)c2c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,419.41,5.87598,2,5
CHEMBL4754946,N#Cc1cccc(/C=C/C(=O)Nc2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,443.869,5.68948,2,5
CHEMBL4779639,N#Cc1cccc(CNc2cc3c(Nc4ccc(F)c(Cl)c4)ncnc3cc2O)c1,Antiviral activity against Middle East respiratory syndrome coronavirus MERS-CoV/KOR/KNIH/002_05_2015 infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect after 24 hrs by immunofluorescence assay,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,419.847,5.35528,3,6
CHEMBL4754320,O=c1[nH]c(Nc2cc(F)cc(F)c2)nc2cc(Cl)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,390,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,307.687,3.5983,2,3
CHEMBL4741240,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2cc(Cl)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,930,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,340.597,4.6269,2,3
CHEMBL4743044,O=c1[nH]c(Nc2cc(F)cc(F)c2)nc2cc(C(F)(F)F)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,730,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,341.239,3.9637,2,3
CHEMBL4760783,O=c1[nH]c(Nc2cc(F)cc(F)c2)nc2c(Cl)ccc(Cl)c12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,790,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,342.132,4.2517,2,3
CHEMBL4752849,O=c1[nH]c(Nc2cc(F)cc(F)c2)nc2c(Cl)c(Cl)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,830,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,342.132,4.2517,2,3
CHEMBL4743584,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2cc(C(F)(F)F)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,960,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,374.149,4.9923,2,3
CHEMBL4748808,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2cc([N+](=O)[O-])ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,inactive,25000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,351.149,3.8817,2,5
CHEMBL4785508,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2c(Cl)ccc(Cl)c12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,620,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,375.042,5.2803,2,3
CHEMBL4799890,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2c(Cl)c(Cl)ccc12,Antiviral activity against MERS-CoV infected in African green monkey Vero cells assessed as inhibition of viral infection by measuring reduction in spike protein level by immunofluorescence microscopic analysis,F,Middle East respiratory syndrome-related coronavirus,Middle East respiratory syndrome-related coronavirus,active,880,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,375.042,5.2803,2,3
CHEMBL194398,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C)Cc1ccccc1,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,870000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,580.682,2.68582,3,8
CHEMBL393608,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,547.653,1.39862,4,8
CHEMBL238216,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,300000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,581.67,1.59522,4,8
CHEMBL235873,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,15000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,659.781,0.8706,6,9
CHEMBL397154,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,625.764,0.674,6,9
CHEMBL238217,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC=C(C)C)CC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,80000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,636.787,2.0748,5,9
CHEMBL196635,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC=C(C)C)CC(=O)[C@@H](NC(=O)c1cc(C)on1)C(C)C,Inhibition of SARS-CoV 3C-like protease by FRET based microplate assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,800000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,558.676,2.79942,3,8
CHEMBL522710,O=C(O)/C(O)=C/C(=O)c1cccc(NCc2ccc(Cl)cc2)c1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,11000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.6613,3,4
CHEMBL492771,O=C(O)/C(O)=C/C(=O)c1cccc(OCc2ccc(Cl)cc2)c1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492771,O=C(O)/C(O)=C/C(=O)c1cccc(OCc2ccc(Cl)cc2)c1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,24400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492772,O=C(O)/C(O)=C/C(=O)c1ccccc1OCc1ccc(Cl)cc1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,28700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492768,O=C(O)/C(O)=C/C(=O)c1ccc(OCc2ccccc2)cc1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,39900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL492768,O=C(O)/C(O)=C/C(=O)c1ccc(OCc2ccccc2)cc1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,41300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL492769,O=C(O)/C(O)=C/C(=O)c1ccc(OCc2ccc(Cl)cc2)cc1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492770,O=C(O)/C(O)=C/C(=O)c1cccc(OCc2ccccc2)c1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL499444,O=C(O)/C(O)=C/C(=O)c1ccccc1OCc1ccccc1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL492772,O=C(O)/C(O)=C/C(=O)c1ccccc1OCc1ccc(Cl)cc1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492571,O=C(O)/C(O)=C/C(=O)c1cccc(NCc2ccccc2)c1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,297.31,3.0079,3,4
CHEMBL522710,O=C(O)/C(O)=C/C(=O)c1cccc(NCc2ccc(Cl)cc2)c1,Inhibition of ATPase activity of SCV helicase assessed as phosphate release by colorimetric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.6613,3,4
CHEMBL492769,O=C(O)/C(O)=C/C(=O)c1ccc(OCc2ccc(Cl)cc2)cc1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,332.739,3.6282,2,4
CHEMBL492770,O=C(O)/C(O)=C/C(=O)c1cccc(OCc2ccccc2)c1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL499444,O=C(O)/C(O)=C/C(=O)c1ccccc1OCc1ccccc1,Inhibition of SCV helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,298.294,2.9748,2,4
CHEMBL221366,O=C(Oc1cccnc1)c1cccs1,Inhibition of SARS coronavirus isolate Tor2 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,active,500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,205.238,2.3623,0,4
CHEMBL518593,C(\C1=C2Sc3ccccc3N2CC1)=C1/CC[n+]2c1sc1ccccc12,Inhibition of SARS Coronavirus 3C-like protease expressed in Escherichia coli,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,361.515,5.2035,0,3
CHEMBL478987,CCN1/C(=C\C=c2/s/c(=C\c3sc4ccccc4[n+]3CC)n(CC)c2=O)Sc2ccccc21,Inhibition of SARS Coronavirus 3C-like protease expressed in Escherichia coli,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,492.715,4.5347,0,6
CHEMBL549646,O=c1cc(CNCc2ccc(Cl)cc2)oc2ccc(O)c(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.1474,3,5
CHEMBL549646,O=c1cc(CNCc2ccc(Cl)cc2)oc2ccc(O)c(O)c12,Inhibition of SARS coronavirus helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.1474,3,5
CHEMBL560136,O=c1cc(CNCc2cccc(Cl)c2)oc2ccc(O)c(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.1474,3,5
CHEMBL560136,O=c1cc(CNCc2cccc(Cl)c2)oc2ccc(O)c(O)c12,Inhibition of SARS coronavirus helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,331.755,3.1474,3,5
CHEMBL560392,N#Cc1cccc(CNCc2cc(=O)c3c(O)c(O)ccc3o2)c1,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,322.32,2.36568,3,6
CHEMBL560392,N#Cc1cccc(CNCc2cc(=O)c3c(O)c(O)ccc3o2)c1,Inhibition of SARS coronavirus helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,322.32,2.36568,3,6
CHEMBL50,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.238,1.988,5,7
CHEMBL556501,O=c1c(O)c(-c2ccc3c(c2)OCO3)oc2cc(O)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,314.249,2.3055,3,7
CHEMBL556501,O=c1c(O)c(-c2ccc3c(c2)OCO3)oc2cc(O)cc(O)c12,Inhibition of SARS coronavirus helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,314.249,2.3055,3,7
CHEMBL550256,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(OCc3ccc(Cl)cc3)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,20900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,426.808,4.5148,4,7
CHEMBL551130,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(OCc3cccc(Cl)c3)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,426.808,4.5148,4,7
CHEMBL551131,N#Cc1cccc(COc2cc(O)c3c(=O)c(O)c(-c4ccc(O)c(O)c4)oc3c2)c1,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,25400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,417.373,3.73308,4,8
CHEMBL551334,O=c1c(O)c(-c2ccc3c(c2)OCO3)oc2cc(OCc3ccc(Cl)cc3)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,438.819,4.8323,2,7
CHEMBL560933,O=c1c(O)c(-c2ccc3c(c2)OCO3)oc2cc(OCc3cccc(Cl)c3)cc(O)c12,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,438.819,4.8323,2,7
CHEMBL560933,O=c1c(O)c(-c2ccc3c(c2)OCO3)oc2cc(OCc3cccc(Cl)c3)cc(O)c12,Inhibition of SARS coronavirus helicase assessed as duplex-DNA unwinding by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,15400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,438.819,4.8323,2,7
CHEMBL551529,N#Cc1cccc(COc2cc(O)c3c(=O)c(O)c(-c4ccc5c(c4)OCO5)oc3c2)c1,Inhibition of ATPase activity of SARS coronavirus helicase assessed as phosphate release by malachite green assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,42900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,429.384,4.05058,2,8
CHEMBL1448,O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,Inhibition of SARS Co-V 3CL protease,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,40000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,327.123,3.8595,2,4
CHEMBL301982,CC1=C(O)C(=O)C=C2C1=CC=C1[C@@]3(C)CC[C@@]4(C)CC[C@@](C)(C(=O)O)C[C@H]4[C@]3(C)CC[C@@]21C,Inhibition of 3C-like protease of SARS coronavirus assessed as concentration of FRET peptide for 60 mins,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,450.619,6.6977,2,3
CHEMBL1092797,Cc1c(O)c(O)cc2c1CC=C1[C@@]3(C)CC[C@@]4(C)CC[C@@](C)(C(=O)O)C[C@H]4[C@]3(C)CC[C@]12C,Inhibition of 3C-like protease of SARS coronavirus assessed as concentration of FRET peptide for 60 mins,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,21700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,452.635,6.64392,3,3
CHEMBL116438,COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,Inhibition of 3C-like protease of SARS coronavirus assessed as concentration of FRET peptide for 60 mins,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,23500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,368.385,3.8526,3,6
CHEMBL1277944,O=C(O)c1ccc(/C=C2\C(=O)N(c3ccccc3)N=C2c2ccccc2)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,18000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,368.392,4.2193,1,3
CHEMBL1278125,O=C(O)c1ccc(/C=C2\C(=O)N(c3ccc(Cl)cc3)N=C2c2ccccc2)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,402.837,4.8727,1,3
CHEMBL1276871,COc1ccc(N2N=C(c3ccccc3)/C(=C/c3ccc(C(=O)O)cc3)C2=O)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,12000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,398.418,4.2279,1,4
CHEMBL1277047,O=C(O)c1ccc(/C=C2\C(=O)N(c3ccc(OC(F)(F)F)cc3)N=C2c2ccccc2)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,42000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,452.388,5.1179,1,4
CHEMBL1277135,O=C(O)c1ccc(/C=C2\C(=O)N(c3cccc(Cl)c3)N=C2c2ccccc2)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,402.837,4.8727,1,3
CHEMBL1277136,O=C(O)c1ccc(/C=C2\C(=O)N(c3ccc(Cl)c(Cl)c3)N=C2c2ccccc2)cc1,Inhibition of SARS coronavirus 3C-like protease by fluorescence plate reader analysis,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,24300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,437.282,5.5261,1,3
CHEMBL197310,CC(C)c1cc2c(cc1O)[C@@]1(C)CCC[C@@](C)(CO)[C@@H]1CC2,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,220800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.458,4.5182,2,2
CHEMBL1277661,CC(C)c1cc2c(cc1O)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC2,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,233400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.458,4.5166,2,2
CHEMBL197308,CC(C)c1cc2c(cc1O)[C@@]1(C)CCCC(C)(C)[C@@H]1CC2,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,49600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,286.459,5.5458,1,1
CHEMBL1277662,CC(C)c1cc2c(cc1O)[C@@]1(C)CCC[C@@](C)(C=O)[C@@H]1CC2,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,163200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,300.442,4.7248,1,2
CHEMBL1277754,CC(=O)Oc1cc2c(cc1C(C)C)CC[C@@H]1[C@]2(C)CCC[C@@]1(C)CO,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,128900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,344.495,4.7379,1,3
CHEMBL12798,COC(=O)[C@]1(C)CCC[C@]2(C)c3ccc(C(C)C)cc3CC[C@H]21,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,207000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,314.469,4.9933,0,2
CHEMBL512164,C=C[C@@]1(C)CC[C@H]2C(=CC[C@H]3[C@](C)(C(=O)O)CCC[C@]23C)C1,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,283500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.458,5.2062,1,1
CHEMBL1277840,C=C1CC[C@H]2[C@](C)(CO)CCC[C@]2(C)[C@H]1CC/C(C)=C\CO,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,137700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,306.49,4.4764,2,2
CHEMBL378188,COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1-c1c(O)cc(O)c2c(=O)cc(-c3ccc(O)cc3)oc12,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,72300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,552.491,5.437,5,10
CHEMBL377324,COc1cc(O)c2c(=O)cc(-c3ccc(OC)c(-c4c(O)cc(O)c5c(=O)cc(-c6ccc(O)cc6)oc45)c3)oc2c1,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,32000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,566.518,5.74,4,10
CHEMBL208908,COc1ccc(-c2cc(=O)c3c(O)cc(O)c(-c4cc(-c5cc(=O)c6c(O)cc(OC)cc6o5)ccc4OC)c3o2)cc1,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,38400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,580.545,6.043,3,10
CHEMBL28,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,280800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,270.24,2.5768,3,5
CHEMBL151,O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,20000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,286.239,2.2824,4,6
CHEMBL50,O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,23800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.238,1.988,5,7
CHEMBL71893,CC(C)C1=CC2=CC[C@H]3[C@](C)(C(=O)O)CCC[C@]3(C)[C@H]2CC1,Inhibition of SARS coronavirus 3C-like protease after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,189100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.458,5.2062,1,1
CHEMBL1774322,Nc1nc(CSc2nnc(-c3cccc4ccccc34)n2-c2ccccc2)cs1,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,58350,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,415.547,5.4185,1,7
CHEMBL1774323,COc1cc(C2C(C(=O)c3ccc(OCC(C)C)cc3C)=C(O)C(=O)N2CCN(C)C)ccc1O,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,62790,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,482.577,3.88392,2,7
CHEMBL1774324,Cc1nc(C)c(C(=O)C2=C(O)C(=O)N(CCCN3CCOCC3)C2c2cccc([N+](=O)[O-])c2)s1,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,101380,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,486.55,2.96874,1,9
CHEMBL1774325,COc1cc(/C=N/NC(=O)/C(=C\c2ccccc2)NC(=O)c2ccccc2)cc(OC)c1O,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,77090,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,445.475,3.3306,3,6
CHEMBL1774326,O=C(CSc1ncnc2c1sc1nc(N3CCOCC3)c3c(c12)CCCC3)NCc1ccco1,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,90720,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,495.63,3.9564,1,9
CHEMBL1350514,Cc1ccc(C(=O)N/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)C(=O)NCCCN(C)C)cc1,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,38570,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,476.533,4.00202,2,6
CHEMBL1315054,Cc1ccc(C(=O)N/C(=C\c2ccc(-c3ccccc3[N+](=O)[O-])o2)C(=O)NCCCN(C)C)cc1,Inhibition of SARS coronavirus recombinant 3C-like protease expressed in Escherichia coli BL21(DE3) after 30 mins by FRET based assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,41390,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,476.533,4.00202,2,6
CHEMBL2316336,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)OCc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@H](C#N)CCC(N)=O,Inhibition of SARS coronavirus 3C-like protease pretreated for 5 mins before substrate addition by fluorimetry,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,39000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,732.836,-1.41042,9,11
CHEMBL2316338,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@H](C#N)CCC(N)=O,Inhibition of SARS coronavirus 3C-like protease pretreated for 5 mins before substrate addition by fluorimetry,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,49000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,510.636,0.84518,5,7
CHEMBL2316339,Cc1cc(C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)CCC(N)=O)C(C)C)no1,Inhibition of SARS coronavirus 3C-like protease pretreated for 5 mins before substrate addition by fluorimetry,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,49000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,519.603,0.0469,5,8
CHEMBL473159,Oc1cc(O)cc(O)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,126.111,0.8034,3,3
CHEMBL459393,Oc1cc(O)c(Oc2cc(O)cc(O)c2Oc2cc(O)cc(O)c2-c2c(O)cc(O)cc2O)c(O)c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,177100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,498.396,3.9942,10,12
CHEMBL510508,Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc4oc5c(Oc6cc(O)cc(O)c6)c(O)cc(O)c5c4c2O3)c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,174600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,602.46,6.419,9,14
CHEMBL2391422,Oc1cc(O)cc(Oc2c(O)cc(Oc3c(O)cc(O)cc3O)cc2O)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,164700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,374.301,3.2104,7,9
CHEMBL559870,Oc1cc(O)c2oc3cc(O)c4oc5cc(O)cc(O)c5oc4c3oc2c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,158300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,370.269,4.3238,5,9
CHEMBL559870,Oc1cc(O)c2oc3cc(O)c4oc5cc(O)cc(O)c5oc4c3oc2c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,146500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,370.269,4.3238,5,9
CHEMBL40275,O=C1c2cccc(O)c2C(=O)c2c(O)cc(CO)cc21,Inhibition of recombinant SARS coronavirus 3C-like protease trans-cleavage activity by ELISA,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,132000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,270.24,1.3655,3,5
CHEMBL2391423,Oc1cc(O)cc(Oc2c(Oc3c(O)cc(O)cc3O)cc(O)c3c2Oc2c(O)cc(O)cc2O3)c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,112200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,496.38,4.814,8,12
CHEMBL456228,Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(Oc4c(O)cc(O)cc4O)cc2O3)c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,112000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,496.38,4.814,8,12
CHEMBL8145,O=c1c(-c2ccc(O)cc2)coc2cc(O)ccc12,Inhibition of recombinant SARS coronavirus 3C-like protease trans-cleavage activity by ELISA,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,105000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,254.241,2.8712,2,4
CHEMBL508791,Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(Oc4c(O)cc(Oc5c(O)cc(O)c6c5Oc5c(O)cc(O)cc5O6)cc4O)cc2O3)c1,Inhibition of SARS coronavirus 3C-like protease cis-cleavage activity transfected in african green monkey Vero cells using SAVLQSGFRK as substrate after 5 hrs by luciferase reporter gene assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,68100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,742.554,7.6211,11,18
CHEMBL399121,COc1ccc([C@@H]2CC(=O)c3c(O)cc(O)cc3O2)cc1O,Inhibition of recombinant SARS coronavirus 3C-like protease trans-cleavage activity by ELISA,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,60000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,302.282,2.5185,3,6
CHEMBL456228,Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc(Oc4c(O)cc(O)cc4O)cc2O3)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,42100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,496.38,4.814,8,12
CHEMBL459393,Oc1cc(O)c(Oc2cc(O)cc(O)c2Oc2cc(O)cc(O)c2-c2c(O)cc(O)cc2O)c(O)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,22500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,498.396,3.9942,10,12
CHEMBL510508,Oc1cc(O)cc(Oc2c(O)cc(O)c3c2Oc2c(O)cc4oc5c(Oc6cc(O)cc(O)c6)c(O)cc(O)c5c4c2O3)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,16700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,602.46,6.419,9,14
CHEMBL2391423,Oc1cc(O)cc(Oc2c(Oc3c(O)cc(O)cc3O)cc(O)c3c2Oc2c(O)cc(O)cc2O3)c1,Inhibition of C-terminal His6-tagged recombinant SARS coronavirus 3C-like protease trans-cleavage activity expressed in Escherichia coli BL21 (DE3) using Dabcyl-KTSAVLQSGFRKME as substrate after 60 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,496.38,4.814,8,12
CHEMBL2441745,CC(C)C[C@H](NC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)C(=O)NC(C)C,Inhibition of SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,active,610,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,685.822,3.3129,5,7
CHEMBL2441741,CC(C)C[C@H](NC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)OCc1ccccc1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,Inhibition of SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,active,230,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.716,3.4181,4,6
CHEMBL3099547,CN1C(=O)C(=O)c2cc(S(=O)(=O)N3CCN(CCc4ccccc4)CC3)ccc21,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13860,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,413.499,1.3947,0,5
CHEMBL3099546,CN1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)C(=O)N3Cc2ccc3ccccc3c2)CC1,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,82910,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,449.532,2.5054,0,5
CHEMBL3099545,CN1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)C(=O)N3Cc2ccccc2)CC1,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,67200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,399.472,1.3522,0,5
CHEMBL3099544,CN1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)C(=O)N3C)CC1,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,11830,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,323.374,-0.2182,0,5
CHEMBL484273,O=C1Nc2ccc(S(=O)(=O)N3CCOCC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,12660,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.304,-0.1577,1,5
CHEMBL3099540,O=C1Nc2ccc(S(=O)(=O)N3CCN(c4ccccn4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,51330,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,372.406,0.7273,1,6
CHEMBL3099539,O=C1Nc2ccc(S(=O)(=O)N3CCN(C(=O)c4ccco4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10070,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,389.389,0.5611,1,6
CHEMBL3099538,O=C1Nc2ccc(S(=O)(=O)N3CCN(CCc4ccccc4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,34910,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,399.472,1.3704,1,5
CHEMBL3099537,COc1cc(CN2CCN(S(=O)(=O)c3ccc4c(c3)C(=O)C(=O)N4)CC2)cc(OC)c1OC,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,32080,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,475.523,1.3537,1,8
CHEMBL3099536,O=C1Nc2ccc(S(=O)(=O)N3CCN(Cc4cccc(Cl)c4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,31710,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,419.89,1.9813,1,5
CHEMBL3099535,O=C1Nc2ccc(S(=O)(=O)N3CCN(c4cccc(C(F)(F)F)c4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,439.415,2.3511,1,5
CHEMBL3099534,O=C1Nc2ccc(S(=O)(=O)N3CCN(c4ccc(F)cc4)CC3)cc2C1=O,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,389.408,1.4714,1,5
CHEMBL3099533,CN1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)C(=O)N3)CC1,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,76740,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,309.347,-0.2425,1,5
CHEMBL3099528,CC1CCN(S(=O)(=O)c2ccc3c(c2)C(=O)C(=O)N3Cc2ccc3ccccc3c2)CC1,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,17820,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,448.544,3.9899,0,4
CHEMBL3099525,O=C1C(=O)N(Cc2ccc3ccccc3c2)c2ccc(S(=O)(=O)N3CCOCC3)cc21,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,39870,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,436.489,2.5902,0,5
CHEMBL3099524,O=C1C(=O)N(Cc2ccccc2)c2ccc(S(=O)(=O)N3CCOCC3)cc21,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13860,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,386.429,1.437,0,5
CHEMBL3099522,O=C1C(=O)N(Cc2ccccc2)c2ccc(S(=O)(=O)N3CCCCC3)cc21,Inhibition of GST-tagged SARS coronavirus 3C-like protease by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,14000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,384.457,2.5907,0,4
CHEMBL554041,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC.Cl.Cl,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,25100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,581.726,5.09988,10,4
CHEMBL1876821,CN(CC(=O)NC1CCCC1)S(=O)(=O)c1cccc(Cl)c1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,330.837,2.0193,1,3
CHEMBL3105072,Nc1ccc(F)c(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,334.294,3.2275,2,3
CHEMBL3105071,COc1ccccc1CNC(=O)[C@H](C)NS(=O)(=O)c1ccccc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,348.424,1.6784,2,4
CHEMBL1392147,CCOc1ccc(S(=O)(=O)NCc2ccc3c(c2)OCO3)cc1C,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,349.408,2.60092,1,5
CHEMBL1732790,OCCCc1nc2ccccc2n1CCOc1ccccc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,200000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.37,3.0402,1,4
CHEMBL1488602,COCCOCCn1c(CCCO)nc2ccccc21,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,186000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,278.352,1.6242,1,5
CHEMBL1392147,CCOc1ccc(S(=O)(=O)NCc2ccc3c(c2)OCO3)cc1C,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,76700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,349.408,2.60092,1,5
CHEMBL1732790,OCCCc1nc2ccccc2n1CCOc1ccccc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,74500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,296.37,3.0402,1,4
CHEMBL1478361,COc1ccc(N(CC(=O)NCc2ccco2)S(C)(=O)=O)cc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,61900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,338.385,1.3706,1,5
CHEMBL1906723,COc1ccc(C(=O)Cn2c(NCCO)nc3ccccc32)cc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,40900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,325.368,2.332,2,6
CHEMBL1487869,Cn1cnc2cc(NC(=O)c3ccc(Cl)cc3)ccc21,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,30900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,285.734,3.479,1,3
CHEMBL3105071,COc1ccccc1CNC(=O)[C@H](C)NS(=O)(=O)c1ccccc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,29900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,348.424,1.6784,2,4
CHEMBL3105075,C(=C/c1ccccc1)\C[N+]1(C/C=C/c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,29800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,485.695,7.3352,0,1
CHEMBL3105072,Nc1ccc(F)c(S(=O)(=O)Nc2cccc(C(F)(F)F)c2)c1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,29800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,334.294,3.2275,2,3
CHEMBL1906723,COc1ccc(C(=O)Cn2c(NCCO)nc3ccccc32)cc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,28800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,325.368,2.332,2,6
CHEMBL3105075,C(=C/c1ccccc1)\C[N+]1(C/C=C/c2ccccc2)CCN(C(c2ccccc2)c2ccccc2)CC1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,28300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,485.695,7.3352,0,1
CHEMBL1487869,Cn1cnc2cc(NC(=O)c3ccc(Cl)cc3)ccc21,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,27600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,285.734,3.479,1,3
CHEMBL1488602,COCCOCCn1c(CCCO)nc2ccccc21,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,25600,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,278.352,1.6242,1,5
CHEMBL3105074,O=C(c1cncc(Br)c1)N1CCN(Cc2ccsc2)CC1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,24500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,366.284,2.8636,0,4
CHEMBL554041,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC.Cl.Cl,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,24500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,581.726,5.09988,10,4
CHEMBL3105076,Nc1ncnc2[nH]c(C(F)(F)F)nc12,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,20400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,203.127,0.9539,2,4
CHEMBL1487869,Cn1cnc2cc(NC(=O)c3ccc(Cl)cc3)ccc21,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,18200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,285.734,3.479,1,3
CHEMBL554041,CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC.Cl.Cl,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay in presence of GSH,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,17800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,581.726,5.09988,10,4
CHEMBL1478361,COc1ccc(N(CC(=O)NCc2ccco2)S(C)(=O)=O)cc1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,16100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,338.385,1.3706,1,5
CHEMBL3105076,Nc1ncnc2[nH]c(C(F)(F)F)nc12,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,13900,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,203.127,0.9539,2,4
CHEMBL3105074,O=C(c1cncc(Br)c1)N1CCN(Cc2ccsc2)CC1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,366.284,2.8636,0,4
CHEMBL1876821,CN(CC(=O)NC1CCCC1)S(=O)(=O)c1cccc(Cl)c1,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,active,940,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,330.837,2.0193,1,3
CHEMBL3105073,S=C(NCc1cccnc1)SCc1cc(Cl)sc1Cl,Inhibition of SARS coronavirus 3C-like protease using 5-FAM-TSATLQSGFRK(QXL520)-NH2 as substrate preincubated for 5 mins followed by substrate addition measured after 6 mins by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,active,160,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,349.333,4.7578,1,4
CHEMBL3810366,CC1=NN(c2cccc(C(=O)O)c2)C(=O)/C1=C\c1ccc(-c2cc(Cl)ccc2C(=O)O)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,450.834,4.8025,2,5
CHEMBL3810109,O=C(O)c1cccc(N2N=C(C(F)(F)F)/C(=C/c3ccc(-c4cc(Cl)ccc4C(=O)O)o3)C2=O)c1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,504.804,5.3449,2,5
CHEMBL3808558,O=C(O)c1cccc(N2N=C(C(F)(F)F)/C(=C\c3ccc(-c4ccccc4C(=O)O)o3)C2=O)c1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,470.359,4.6915,2,5
CHEMBL3808795,O=C(O)c1cccc(N2N=C(c3ccccc3)/C(=C/c3ccc(-c4cc(Cl)ccc4C(=O)O)o3)C2=O)c1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,44700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,512.905,5.8309,2,5
CHEMBL3810010,CC1=NN(c2ccccc2)C(=O)/C1=C\c1ccc(-c2cc(Cl)ccc2C(=O)O)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,406.825,5.1043,1,4
CHEMBL3810328,O=C(O)c1ccc(Cl)cc1-c1ccc(/C=C2\C(=O)N(c3ccccc3)N=C2c2ccccc2)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,16400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,468.896,6.1327,1,4
CHEMBL3808658,O=C(O)c1ccc(Cl)cc1-c1ccc(/C=C2\C(=O)N(c3ccc(F)cc3)N=C2c2ccccc2)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,20200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,486.886,6.2718,1,4
CHEMBL3810058,O=C1/C(=C\c2ccc(-c3ccccc3)o2)C(c2ccccc2)=NN1c1ccccc1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,390.442,5.7811,0,3
CHEMBL3809159,CC1=NN(c2cccc(C(=O)O)c2)C(=O)/C1=C\c1ccc(-c2ccccc2)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,372.38,4.4509,1,4
CHEMBL3810361,O=C(O)c1ccccc1-c1ccc(/C=C2\C(=O)N(c3ccccc3)N=C2c2ccccc2)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,41200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,434.451,5.4793,1,4
CHEMBL3810325,O=C(O)c1ccccc1-c1ccc(/C=C2\C(=O)N(c3ccc(F)cc3)N=C2c2ccccc2)o1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,37500,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,452.441,5.6184,1,4
CHEMBL3809506,CC(C)c1ccc(N2N=C(c3ccccc3)/C(=C/c3ccc(-c4ccccc4C(=O)O)o3)C2=O)cc1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,11700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,476.532,6.6027,1,4
CHEMBL3809498,N#Cc1ccc(N2N=C(c3ccccc3)/C(=C/c3ccc(-c4ccccc4C(=O)O)o3)C2=O)cc1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,18700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,459.461,5.35098,1,5
CHEMBL3809059,COc1ccc(N2N=C(c3ccccc3)/C(=C/c3ccc(-c4ccccc4C(=O)O)o3)C2=O)cc1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,30700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,464.477,5.4879,1,5
CHEMBL3809833,O=C(O)c1cccc(N2N=C(c3ccccc3)/C(=C/c3ccco3)C2=O)c1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,358.353,3.8123,1,4
CHEMBL3809926,O=C(O)c1cccc(N2N=C(c3ccccc3)/C(=C/c3ccc(OCc4ccccc4)cc3)C2=O)c1,Inhibition of SARS coronavirus recombinant 3CL-PRO expressed in Escherichia coli JM109 cells using Dabcyl-KTSAVLQSGFRKME-Edans as fluorogenic substrate by fluorometric assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,15700,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,474.516,5.7983,1,4
CHEMBL3818400,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O,Inhibition of SARS coronavirus main proteinase 3C-like protease,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,604.614,-4.3257,10,10
CHEMBL3818761,CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O,Inhibition of SARS coronavirus main proteinase 3C-like protease,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,50000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,626.668,-3.8346,10,10
CHEMBL3818028,CC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)O)[C@@H](C)O,Inhibition of SARS coronavirus main proteinase 3C-like protease,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,20000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,605.558,-6.4964,11,11
CHEMBL4209146,CC(C)C[C@H](NC(=O)OC1CCN(S(C)(=O)=O)CC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,Inhibition of SARS coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,28800,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,474.58,-0.2388,3,7
CHEMBL4213159,CC(C)C[C@H](NC(=O)OC1CCN(S(C)(=O)=O)CC1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-].[Na+],Inhibition of SARS coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,SARS coronavirus,Replicase polyprotein 1ab,inactive,42100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,578.642,-4.5701,4,10
CHEMBL480,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,390,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,369.368,3.51522,1,4
CHEMBL178459,Cc1c(-c2cnccn2)ssc1=S,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,210,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.351,3.30451,0,5
CHEMBL3545157,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,80,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.4,3.2622,0,5
CHEMBL4303595,O=C1C=Cc2cc(Br)ccc2C1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,40,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,237.052,2.2277,0,2
CHEMBL55400,Nc1ccc2cc3ccc(N)cc3nc2c1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,360,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,209.252,2.5524,2,3
CHEMBL1886408,CCOC(=O)Cc1ccc(-c2ccccc2)cc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,200,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,240.302,3.4592,0,2
CHEMBL505670,O=[N+]([O-])c1ccc(Sc2cccc[n+]2[O-])c2nonc12,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,100,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,290.26,1.9156,0,7
CHEMBL460499,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,160,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,257.265,0.8137,2,4
CHEMBL1096979,NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,140,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,257.246,-1.7562,7,7
CHEMBL164,O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,220,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,318.237,1.6936,6,8
CHEMBL1422849,CCN1CCN(C(c2ccc(C(F)(F)F)cc2)c2ccc3cccnc3c2O)CC1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,150,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,415.459,4.6861,1,4
CHEMBL284861,Cn1sc(=O)n(Cc2ccccc2)c1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,140,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,222.269,0.6568,0,5
CHEMBL3963349,COC(=O)CC[C@H](NC(=O)[C@H](CC(=O)OC)NC(=O)OCc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)C(C)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,10,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,668.672,0.0098,4,12
CHEMBL3797437,Oc1cc2c(cc1C(c1ccc(C(F)(F)F)cc1)N1CCOCC1)OCO2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,540,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,381.35,3.5613,1,5
CHEMBL289356,Sc1nnc(Nc2ccccc2)s1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,390,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,209.299,2.5704,2,5
CHEMBL1725120,Cc1ccc(C)c(-n2sc3cc(F)ccc3c2=O)c1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,20,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,273.332,3.80814,0,3
CHEMBL1356238,[O-][n+]1ccccc1S,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,50,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,127.168,0.6087,1,2
CHEMBL105712,O=C(CCl)c1ccccc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,190,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,154.596,2.1081,0,1
CHEMBL508112,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,160,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,332.5,5.7054,0,6
CHEMBL1397952,CCOc1cc(C(Nc2cc(C)ccn2)c2ccc3cccnc3c2O)ccc1OC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,270,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,415.493,5.25262,2,6
CHEMBL192627,O=C1C(Cl)=C(Cl)C(=O)C(Cl)=C1Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,20,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,245.876,2.5166,0,2
CHEMBL1917204,Cc1ccc(-n2sc(=O)n(Cc3ccc(F)cc3)c2=O)cc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,150,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,316.357,2.55652,0,5
CHEMBL1200930,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C.[Na+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,740,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,381.433,-0.37748,0,5
CHEMBL1475252,COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2n1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,970,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,346.412,2.29474,1,6
CHEMBL406050,CCC(C)SSc1ncc[nH]1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,140,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,188.321,2.9485,1,3
CHEMBL1255778,Cl.NC(CO)C(=O)NNCc1ccc(O)c(O)c1O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,140,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,293.707,-1.3344,7,7
CHEMBL388676,O=C1C2CC=CCC2C(=O)N1SC(Cl)(Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,670,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,300.594,2.9135,0,3
CHEMBL3348861,O=C1c2c(O)cc(O)cc2O[C@H](c2cc(O)c(O)c(O)c2)[C@H]1O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,180,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,320.253,0.8919,6,8
CHEMBL1917204,Cc1ccc(-n2sc(=O)n(Cc3ccc(F)cc3)c2=O)cc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,230,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,316.357,2.55652,0,5
CHEMBL403183,Cc1ccc(S(=O)(=O)/C=C/C#N)cc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,820,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,207.254,1.806,0,3
CHEMBL2097077,C1=CC=C(C(=C1)C2=C3C=C(C(=O)C=C3OC4=C(C(=C(C=C24)Br)[O-])[Hg])Br)C(=O)[O-].O.[Na+].[Na+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,240,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,751.664,-4.1177,0,5
CHEMBL1161936,O=C(O)c1ccc(SSc2ccc(C(=O)O)cn2)nc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,240,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,308.34,2.6724,2,6
CHEMBL120563,CN(C)C(=S)SSC(=S)N(C)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,50,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,240.444,2.0608,0,4
CHEMBL51085,O=c1c2ccccc2[se]n1-c1ccccc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,30,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,274.181,2.0477,0,2
CHEMBL1188627,C/N=c1/nc(-c2ccccc2)n(-c2ccccc2)s1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,980,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,267.357,3.1313,0,4
CHEMBL510038,Nc1nnc(Sc2ncc([N+](=O)[O-])s2)s1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,30,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,261.313,1.6362,1,9
CHEMBL964,CCN(CC)C(=S)SSC(=S)N(CC)CC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,220,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,296.552,3.6212,0,4
CHEMBL1474701,O=C1C=CC(=O)C2=C1C1c3ccccc3C2c2ccccc21,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,240,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,284.314,3.282,0,2
CHEMBL1408862,O=[N+]([O-])C(Br)(CO)CO,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,420,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,199.988,-0.6611,2,4
CHEMBL4303595,O=C1C=Cc2cc(Br)ccc2C1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,160,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,237.052,2.2277,0,2
CHEMBL571700,CN(C)C(=S)SC(=S)N(C)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,940,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,208.377,1.4126,0,3
CHEMBL472940,Oc1ccc2ccccc2c1SSc1c(O)ccc2ccccc12,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,510,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,350.464,6.2036,2,4
CHEMBL1374426,CCC(=O)OCN1C(=O)C=CC1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,290,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,183.163,-0.1779,0,4
CHEMBL518800,CC[C@H](CO)Nc1nc(NCc2ccc(-c3ccccn3)cc2)c2ncn(C(C)C)c2n1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,840,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,431.544,4.2641,3,8
CHEMBL596674,CC(C)N(CCC(=O)c1ccc2ccccc2c1)Cc1ccccc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,580,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,331.459,5.3232,0,2
CHEMBL164,O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,400,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,318.237,1.6936,6,8
CHEMBL270299,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,840,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,249.335,2.79508,0,3
CHEMBL4303312,Oc1c(I)cc(I)c(O)c1I,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,330,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,487.8,2.9116,2,2
CHEMBL4303361,Oc1cc(CNC(=S)/C=C/c2cc(O)c(O)c(Br)c2)cc(O)c1O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,480,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,412.261,3.1075,6,6
CHEMBL4303622,N#CSc1cc(SC#N)c(N)nc1N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,410,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,223.286,1.39236,2,7
CHEMBL297453,O=C(O[C@@H]1Cc2c(O)cc(O)cc2O[C@@H]1c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,720,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,458.375,2.2332,8,11
CHEMBL508338,CC[Hg]SC1=CC=CC=C1C(=O)[O-].[Na+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,10,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,404.816,-1.4181,0,3
CHEMBL1591074,c1ccc2sc(SNC3CCCCC3)nc2c1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,770,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,264.419,4.2257,1,4
CHEMBL465704,Nc1ccc2cc3ccc(N)cc3nc2c1.Nc1ccc2cc3ccc(N)cc3nc2c1.O=S(=O)(O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,830,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,516.583,4.452,6,8
CHEMBL2107818,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(CO)=N/NC(=O)CCCCCN1C(=O)C=CC1=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,580,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
CHEMBL8260,O=c1cc(-c2ccccc2)oc2cc(O)c(O)c(O)c12,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,20,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,270.24,2.5768,3,5
CHEMBL508280,O=[N+]([O-])c1cnc(Sc2nnc(O)n2-c2ccc3c(c2)OCCO3)s1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,379.379,2.26,1,11
CHEMBL1333953,CC(=O)O[Hg]C1=CC=CC=C1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,10,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,336.74,0.8725,0,2
CHEMBL1616,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,520,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,303.789,3.2717,2,3
CHEMBL477197,Oc1cc2c(cc1O)[C@@H]1c3ccc(O)c(O)c3OC[C@]1(O)C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,220,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,302.282,1.3205,5,6
CHEMBL1449651,N.S=C(S)N1CCCC1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,210,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,164.299,1.4589,2,2
CHEMBL3545157,O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,150,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.4,3.2622,0,5
CHEMBL178459,Cc1c(-c2cnccn2)ssc1=S,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,620,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.351,3.30451,0,5
CHEMBL1382627,Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,F,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,750,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,357.143,1.4504,1,5
CHEMBL2316746,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)c1nc2ccccc2s1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,94,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,635.787,3.9719,4,8
CHEMBL213543,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,286,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,572.703,2.5986,4,7
CHEMBL4796938,O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2[nH]1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
CHEMBL4764751,O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1cccc(F)c1)NC(=O)c1cc2ccccc2[nH]1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,23,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
CHEMBL4857345,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)C(=O)NC(C)C,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,65,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,601.745,1.9631,5,7
CHEMBL2402501,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)c1nc2ccccc2s1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,536.654,3.8311,3,7
CHEMBL4868590,CC(C)(C)C(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,504.672,1.7758,3,5
CHEMBL92708,CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,362.47,3.2014,2,4
CHEMBL4850298,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,403.479,1.5374,3,5
CHEMBL3559293,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)O,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,34,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
CHEMBL4518490,CCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,461.603,3.3422,3,5
CHEMBL64925,CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,475.63,3.5882,3,5
CHEMBL4777223,COc1cccc2[nH]c(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C(=O)CO)cc12,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,8,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,472.542,0.8934,5,6
CHEMBL231813,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,679.863,2.4459,4,8
CHEMBL4852855,C[C@@H](OC(C)(C)C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H](C=O)C[C@@H]1CCNC1=O,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,9,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.757,3.1501,4,7
CHEMBL4796938,O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2[nH]1,Inhibition of recombinant SARS CoV-2 main protease expressed in Escherichia coli using MCA-AVLQ SGFR-Lys (Dnp)-Lys-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,53,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
CHEMBL4764751,O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1cccc(F)c1)NC(=O)c1cc2ccccc2[nH]1,Inhibition of recombinant SARS CoV-2 main protease expressed in Escherichia coli using MCA-AVLQ SGFR-Lys (Dnp)-Lys-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,40,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
CHEMBL4796938,O=C[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)c1cc2ccccc2[nH]1,Inhibition of recombinant SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of DABCYL-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu-EDANS substrate and measured after 30 mins by microplate reader method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,31,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
CHEMBL3559293,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)O,Inhibition of recombinant SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of DABCYL-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu-EDANS substrate and measured after 30 mins by microplate reader method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,31,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
CHEMBL92708,CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10690,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,362.47,3.2014,2,4
CHEMBL3559293,CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)O,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,30,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
CHEMBL231813,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,Inhibition of SARS-CoV-2 3CL protease using Dabcyl-KTSAVLQSGFRKME-Edans substrate measured by flourimetric plate reader method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,11470,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,679.863,2.4459,4,8
CHEMBL4868572,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,715.878,-0.9674,7,10
CHEMBL4859153,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,744.88,-2.99623,10,11
CHEMBL4846937,CC[C@@H]1NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2CC2)NC(=O)[C@H](C(C)(C)C)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,713.862,-1.0693,7,10
CHEMBL4873791,C[C@@H](O)[C@@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2CC2)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,717.806,-3.7638,9,12
CHEMBL4871930,CC(C)C[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,715.878,-0.9674,7,10
CHEMBL4855260,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,703.823,-2.6311,8,11
CHEMBL4864163,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,829.982,-2.5941,9,12
CHEMBL4867088,CC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2CC2)NC(=O)[C@H](C(C)(C)C)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,856.02,-2.0599,9,12
CHEMBL4872397,CC[C@@H]1NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC2CC2)NC(=O)[C@H](C(C)(C)C)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,800.94,-2.5922,9,12
CHEMBL4851348,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,901.061,-3.0894,10,13
CHEMBL4851196,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,845.981,-3.6217,10,13
CHEMBL4876522,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(=O)O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,716.862,-0.3681,7,10
CHEMBL4858748,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCC(=O)O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,745.864,-2.39693,10,11
CHEMBL4848940,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,815.955,-2.9842,9,12
CHEMBL4847752,NCCCC[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,766.882,-2.9615,9,12
CHEMBL4873945,CC(C)C[C@@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSC(=N2)c2cc(ccn2)C[C@@H](C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,1451.678,-7.57813,21,22
CHEMBL4846266,CC[C@@H]1NC(=O)[C@@H](N)CCNC(=O)[C@@H]2CSC(=N2)c2cccc(n2)C2=N[C@@H](CS2)C(=O)NCCCC[C@@H](C(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)(C)C)NC1=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,986.236,-1.3837,10,15
CHEMBL4877763,CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC1CC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccnc(C#N)c1)C(N)=O)C(C)(C)C,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,627.747,-1.23072,7,9
CHEMBL4877806,CC[C@H](NC(C)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(N)=O)C(C)(C)C,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,498.625,-0.8015,6,6
CHEMBL4873357,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H]1CSCN1)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccnc(C#N)c1)C(N)=O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,100000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,859.024,-2.93552,10,13
CHEMBL4875501,CC(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)C(C)C)[C@@H](C)O,Inhibition of SARS CoV-2 main protease using DABCYL-KTSAVLQ1SGFRKM-E(EDANS)-NH2 as substrate by FRET based assay,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,71000,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,1468.68,-8.35173,23,21
CHEMBL4877358,N=C(N/N=C/c1ccccc1O)c1nonc1NCNc1nonc1C(=N)N/N=C/c1ccccc1O,Inhibition of SARS-CoV-2 main protease,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,110,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.471,1.24344,8,14
CHEMBL4869416,COc1cc(C(NC2=NC(=O)C(CC(=O)Nc3ccc(C(=O)O)cc3)S2)c2c(O)[nH]c(=O)[nH]c2=O)ccc1O,Inhibition of SARS-CoV-2 main protease,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,450,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,555.525,0.887,7,10
CHEMBL4869416,COc1cc(C(NC2=NC(=O)C(CC(=O)Nc3ccc(C(=O)O)cc3)S2)c2c(O)[nH]c(=O)[nH]c2=O)ccc1O,Inhibition of SARS-CoV-2 papain-like protease,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,85,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,555.525,0.887,7,10
CHEMBL4877358,N=C(N/N=C/c1ccccc1O)c1nonc1NCNc1nonc1C(=N)N/N=C/c1ccccc1O,Inhibition of SARS-CoV-2 papain-like protease,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,active,63,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.471,1.24344,8,14
CHEMBL4848534,Cn1cc(SCC(=O)NCc2ccccc2)c2ccccc21,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,26920,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,310.422,3.5868,1,3
CHEMBL4864930,Cn1cc(SCC(=O)N(Cc2ccccc2)Cc2ccccc2)c2ccccc21,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,12300,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,400.547,5.4994,0,3
CHEMBL4854494,COc1ccccc1CNC(=O)CSc1c[nH]c2ccc(Br)cc12,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10720,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,405.317,4.3475,2,3
CHEMBL4852238,COc1ccccc1CNC(=O)CSc1c[nH]c2cc(Br)ccc12,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,10010,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,405.317,4.3475,2,3
CHEMBL4854368,CN(Cc1ccccc1)C(=O)CSc1c[nH]c2c(Br)cccc12,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Severe acute respiratory syndrome coronavirus 2,Replicase polyprotein 1ab,inactive,20890,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,389.318,4.6811,1,2
CID 786691,CC1=CC(=NC(=O)N1S(=O)(=O)C2=CC=C(C=C2)N)C,Binding affinity to 15N-labelled His-tagged Apo-MRES-CoV papain-like protease by TROSY [1H-15N] spectroscopy,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,unspecified,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,279.321,0.67934,1,6
CID 44267478,C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4C3OC(=CC4=O)C5=NNN=N5,Binding affinity to MERS-CoV papain-like protease in presence of Z-Arg-Leu-Arg-Gly-Gly-AMC by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),inactive,unspecified,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,483.528,3.4101,2,7
CID  786691,CC1=CC(=NC(=O)N1S(=O)(=O)C2=CC=C(C=C2)N)C,Reversible inhibition of MERS-CoV papain-like protease assessed as recovery of enzyme activity at 125 times IC50 using Z-Arg-Leu-Arg-Gly-Gly-AMC as substrate incubated for 1 hr followed by 2-fold dilution and measured by fluorescence assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,unspecified,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,279.321,0.67934,1,6
145975487,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2CCN(CC2)C(=O)OC(C)(C)C.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.4,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.667,-2.5946,4,10
145975487,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2CCN(CC2)C(=O)OC(C)(C)C.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.4,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.667,-2.5946,4,10
145978039,CCOC(=O)N1CCC(CC1)OC(=O)NC(CC(C)C)C(=O)NC(CC2CCNC2=O)C(O)S(=O)(=O)[O-].[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.5,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,572.613,-3.3732,4,10
145978039,CCOC(=O)N1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C(O)S(=O)(=O)[O-].[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.5,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,572.613,-3.3732,4,10
145966788,CC(C)CC(C(=O)NC(CC1CCNC1=O)C=O)NC(=O)OC2CCN(CC2)C(=O)OC(C)(C)C,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,496.605,1.7367,3,7
145966788,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OC2CCN(CC2)C(=O)OC(C)(C)C,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,496.605,1.7367,3,7
145972878,CCOC(=O)N1CCC(CC1)OC(=O)NC(CC(C)C)C(=O)NC(CC2CCNC2=O)C=O,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,468.551,0.9581,3,7
145972878,CCOC(=O)N1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,468.551,0.9581,3,7
145964420,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2CCN(CC2)S(=O)(=O)C.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,578.642,-4.5701,4,10
145964420,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2CCN(CC2)S(=O)(=O)C.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,578.642,-4.5701,4,10
145964710,CC(C)CC(C(=O)NC(CC1CCNC1=O)C=O)NC(=O)OC2CCN(CC2)S(=O)(=O)C,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,474.58,-0.2388,3,7
145964710,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OC2CCN(CC2)S(=O)(=O)C,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,474.58,-0.2388,3,7
145975081,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2(CCN(CC2)C(=O)OC(C)(C)C)CC3=CC=CC=C3.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,690.792,-0.9817,4,10
145975081,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2(CCN(CC2)C(=O)OC(C)(C)C)CC3=CC=CC=C3.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,690.792,-0.9817,4,10
145972736,CC(C)CC(C(=O)NC(CC1CCNC1=O)C=O)NC(=O)OC2(CCN(CC2)S(=O)(=O)C)CC3=CC=CC=C3,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,564.705,1.3741,3,7
145972736,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OC2(CCN(CC2)S(=O)(=O)C)CC3=CC=CC=C3,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,564.705,1.3741,3,7
145976006,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OC2(CCN(CC2)C(=O)OC(C)(C)C)CC3=CC=CC=C3,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.8,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,586.73,3.3496,3,7
145976006,CC(C)CC(C(=O)NC(CC1CCNC1=O)C=O)NC(=O)OC2(CCN(CC2)C(=O)OC(C)(C)C)CC3=CC=CC=C3,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.8,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,586.73,3.3496,3,7
145967285,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2(CCN(CC2)S(=O)(=O)C)CC3=CC=CC=C3.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.9,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,668.767,-2.9572,4,10
145967285,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OC2(CCN(CC2)S(=O)(=O)C)CC3=CC=CC=C3.[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,0.9,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,668.767,-2.9572,4,10
2817763,C1=C(C(=NC(=C1SC#N)N)N)SC#N,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,2.3,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,223.286,1.39236,2,7
11427553,C1CN(CCN1)C(=O)C2=CC=C(C=C2)C=CC3=NNC4=CC=CC=C43,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,3.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,332.407,2.7787,2,3
11427553,C1CN(CCN1)C(=O)C2=CC=C(C=C2)/C=C/C3=NNC4=CC=CC=C43,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,3.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,332.407,2.7787,2,3
2747117,C1COC2=C(O1)C=CC(=C2)N3C(=O)NN=C3SC4=NC=C(S4)[N+](=O)[O-],MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,3.8,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,379.379,1.8477,1,10
145964401,CCC1(CCN(CC1)C(=O)OC(C)(C)C)OC(=O)NC(CC(C)C)C(=O)NC(CC2CCNC2=O)C=O,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,6.1,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,524.659,2.5169,3,7
145964401,CCC1(CCN(CC1)C(=O)OC(C)(C)C)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O,Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,6.1,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,524.659,2.5169,3,7
145972809,CCC1(CCN(CC1)C(=O)OC(C)(C)C)OC(=O)NC(CC(C)C)C(=O)NC(CC2CCNC2=O)C(O)S(=O)(=O)[O-].[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.5,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,628.721,-1.8144,4,10
145972809,CCC1(CCN(CC1)C(=O)OC(C)(C)C)OC(=O)NC(CC(C)C)C(=O)NC(CC2CCNC2=O)C(O)S(=O)(=O)[O-].[Na+],Inhibition of Middle East respiratory syndrome-related coronavirus 3CL protease using Dabcyl-KTSAVLQ/SGFRKME-Edans as substrate incubated for 30 mins followed by substrate addition measured after 1 hr by FRET assay,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.5,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,628.721,-1.8144,4,10
5339,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,398.4,3.7016,3,7
5305368,C1COCCN1C2=CC=C(C=C2)C=CC3=NC4=CC=CC=C4C(=C3)C(=O)O,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,360.413,3.94,1,4
5305368,C1COCCN1C2=CC=C(C=C2)/C=C/C3=NC4=CC=CC=C4C(=C3)C(=O)O,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,360.413,3.94,1,4
2816264,CN1C2=C(N=C1N=NC3=C(NC(=O)NC3=O)O)N(C(=O)N(C2=O)C)C,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,348.279,-1.5317,3,11
1643368,CN1C2=CC=CC=C2SC1=CC(=O)COC,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,235.308,2.2854,0,4
1643368,CN\1C2=CC=CC=C2S/C1=C\C(=O)COC,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,235.308,2.2854,0,4
135473051,CC1=CC(=C(C=C1)C)CSC2=NC(=C(C(=O)N2)C#N)C3CCCCC3,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,353.491,4.59842,1,4
786691,CC1=CC(=NC(=O)N1S(=O)(=O)C2=CC=C(C=C2)N)C,Binding affinity to MERS-CoV papain-like protease by SPR analysis,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,279.321,0.67934,1,6
149096,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,361.373,1.544,1,6
149096,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,361.373,1.544,1,6
219104,CCC(C)SSC1=NC=CN1,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,7.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,188.321,2.9485,1,3
3797,CC(C)N(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC3=CC=CC=C3,MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,8.1,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,331.459,5.3232,0,2
390892,C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.Cl.[Cl-],MERS_3CL Pro protease inhibition IC50  by FRET kind of response from peptide substrate,B,ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Betacoronavirus England 1),active,10,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,505.453,1.9601,4,5
CID 14502645,CC(=O)C1C2=C3C4=C(CC1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.038,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
CID 14502645,CC(=O)[C@@H]1C2=C3C4=C(C[C@]1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.038,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
164619101,CC(=O)CC1=C(C(=O)C2=C(C1=O)C(=C(C=C2O)OC)C3=C(C=C(C4=C3C(=O)C(=C(C4=O)OC)CC(=O)C)O)OC)OC,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.17,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,578.526,3.2992,2,12
25068341,CC(=O)C1C2=C3C4=C(CC1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
25068341,CC(=O)[C@H]1C2=C3C4=C(C[C@]1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
2719,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,Inhibition of spike glycoprotein S in SARS-CoV-2 pseudovirus infected in human 293T/ACE2 cells assessed as inhibition of viral infection pretreated the virus for 30 mins followed by viral infection measured after 48 hrs by by luciferase reporter gene assa,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.16,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,319.88,4.8106,1,3
14502645,CC(=O)C1C2=C3C4=C(CC1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Binding affinity to SARS-CoV-2 spike glycoprotein S RBD at 25 degreeC by surface plasmon resonance assay,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.0379,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
14502645,CC(=O)[C@@H]1C2=C3C4=C(C[C@]1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Binding affinity to SARS-CoV-2 spike glycoprotein S RBD at 25 degreeC by surface plasmon resonance assay,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.0379,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
25068341,CC(=O)C1C2=C3C4=C(CC1(C)O)C(=C(C5=C4C(=C6C3=C(C(=O)C=C6OC)C(=C2OC)O)C(=CC5=O)OC)O)OC,Binding affinity to SARS-CoV-2 spike glycoprotein S RBD at 25 degreeC by surface plasmon resonance assay,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,0.0228,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,546.528,3.3207,3,10
2719,CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl,Inhibition of SARS-CoV-2 spike glycoprotein/ His tagged human ACE2 interaction incubated for 1 hr followed by substrate addition and measured after 15 mins by ELISA,B, surface glycoprotein (Severe acute respiratory syndrome coronavirus 2), surface glycoprotein (Severe acute respiratory syndrome coronavirus 2),active,7,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,319.88,4.8106,1,3
690730,C1=CC=C(C=C1)N2C(=S)N=NN2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.36,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,178.22,1.32489,1,4
674768,CCOC(=O)C1=C(SC(=C1C)C2=CC=CC=C2)N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.19,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,261.346,3.48242,1,4
72146,COC1=C(C=CC(=C1)C(=S)N2CCOCC2)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.32,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,253.323,1.4085,1,4
16760394 (Z-Devd-fmk),CC(C)C(C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CCC(=O)OC)NC(=O)C(CC(=O)OC)NC(=O)OCC1=CC=CC=C1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.01,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,668.672,0.0098,4,12
16760394 (Z-Devd-fmk),CC(C)[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.01,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,668.672,0.0098,4,12
2941638,C1=CC(=CC=C1NC(=O)CC2C(=O)N3C(=NC=N3)S2)Br,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.04,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,353.201,2.1839,1,6
34359 (Carbidopa),CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.55,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.232,-0.0531,5,5
34359 (Carbidopa),C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.55,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.232,-0.0531,5,5
3384730 (Ethylpiperazin-1-yl quinolin-8-ol),CCN1CCN(CC1)C(C2=CC=C(C=C2)C(F)(F)F)C3=C(C4=C(C=CC=N4)C=C3)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.15,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,415.459,4.6861,1,4
26436 (Felbinac ethyl),CCOC(=O)CC1=CC=C(C=C1)C2=CC=CC=C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.2,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,240.302,3.4592,0,2
10757 (2-Chloroacetophenone),C1=CC=C(C=C1)C(=O)CCl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.19,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,154.596,2.1081,0,1
3799 (1-(2-Naphthalenyl)-2-propen-1-one),C=CC(=O)C1=CC2=CC=CC=C2C=C1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.24,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,182.222,3.2085,0,1
"2733079 (4-(4-Fluorobenzyl)-2-p-tolyl-1,2,4-thiadiazolidine-3,5-dione)",CC1=CC=C(C=C1)N2C(=O)N(C(=O)S2)CC3=CC=C(C=C3)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.15,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,316.357,2.55652,0,5
2733079,CC1=CC=C(C=C1)N2C(=O)N(C(=O)S2)CC3=CC=C(C=C3)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.23,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,316.357,2.55652,0,5
5353432 ((E)-3-(4-tert-butylphenylsulfonyl)acrylonitrile),CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)C=CC#N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.84,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,249.335,2.79508,0,3
5353432 ((E)-3-(4-tert-butylphenylsulfonyl)acrylonitrile),CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.84,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,249.335,2.79508,0,3
30623 (Razoxane),CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.19,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,268.273,-2.7083,2,6
"9849425 (3,6-Acridinediamine, sulfate (2:1))",C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.OS(=O)(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.83,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,516.583,4.452,6,8
26964 (Benserazide hydrochloride),C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,293.707,-1.3344,7,7
"2817763 (3,5-Dithiocyanatopyridine-2,6-diamine)",C1=C(C(=NC(=C1SC#N)N)N)SC#N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.41,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,223.286,1.39236,2,7
1242,C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.8,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,255.317,2.3754,3,3
8371 (Chloranil),C1(=C(C(=O)C(=C(C1=O)Cl)Cl)Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.02,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,245.876,2.5166,0,2
CID 7099 (Proflavine),C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.36,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,209.252,2.5524,2,3
5353431 ((E)-3-Tosylacrylonitrile),CC1=CC=C(C=C1)S(=O)(=O)C=CC#N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.82,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,207.254,1.806,0,3
5353431 ((E)-3-Tosylacrylonitrile),CC1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.82,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,207.254,1.806,0,3
CID 129010103 (chromen-4-one),CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.66,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.379,0.1943,8,12
CID 129010103 (chromen-4-one),C[C@H]1[C@@H]([C@H]([C@@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C(=C4)O)O)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.66,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.379,0.1943,8,12
65064 ((-)-Epigallocatechin gallate),C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,458.375,2.2332,8,11
65064,C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.72,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,458.375,2.2332,8,11
3194 (Ebselen),C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.03,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,274.181,2.0477,0,2
441386 (Delavirdine mesylate),CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C.CS(=O)(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,552.679,2.2211,4,8
219104 (2-(Sec-butyldisulfanyl)-1h-imidazole),CCC(C)SSC1=NC=CN1,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,188.321,2.9485,1,3
3797,CC(C)N(CCC(=O)C1=CC2=CC=CC=C2C=C1)CC3=CC=CC=C3,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,331.459,5.3232,0,2
7232 -- N-Cyclohexyl-2-benzothiazolesulfenamide,C1CCC(CC1)NSC2=NC3=CC=CC=C3S2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.77,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,264.419,4.2257,1,4
59757974 -- XL-228,CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)N3CCN(CC3)C)NC4=NNC(=C4)C5CC5,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.49,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,437.552,3.296,3,9
"5923508 -- methyl (5Z)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate",CC=C1C(C(=COC1OC2C(C(C(C(O2)CO)O)O)O)C(=O)OC)CC(=O)OCCC3=CC(=C(C=C3)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.38,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,540.518,-0.6342,6,13
"5923508 -- methyl (5Z)-4-[2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl]-5-ethylidene-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4H-pyran-3-carboxylate",C/C=C\1/C(C(=COC1OC2C(C(C(C(O2)CO)O)O)O)C(=O)OC)CC(=O)OCCC3=CC(=C(C=C3)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.38,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,540.518,-0.6342,6,13
"134689197 -- (1R,2R,5S,8R,9R,11R,15S,18R)-9,15,18-trihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one",CC1(CCC(C23C1CC(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.57,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,348.439,1.4048,3,5
"134689197 -- (1R,2R,5S,8R,9R,11R,15S,18R)-9,15,18-trihydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one",CC1(CC[C@@H]([C@]23[C@@H]1C[C@]([C@]45[C@@H]2CC[C@H]([C@H]4O)C(=C)C5=O)(OC3)O)O)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.57,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,348.439,1.4048,3,5
"11837140 -- 5-[(5-Nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine",C1=C(SC(=N1)SC2=NN=C(S2)N)[N+](=O)[O-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.03,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,261.313,1.6362,1,9
5280443 -- Apigenin,C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.02,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,270.24,2.5768,3,5
"6842 -- 3,6-Diamino-10-methylacridinium chloride",C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.[Cl-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.98,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,259.74,-1.0141,2,2
8606 -- Captan,C1C=CCC2C1C(=O)N(C2=O)SC(Cl)(Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.67,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,300.594,2.9135,0,3
"3906779 -- 6-(Benzenesulfinyl)tetrazolo[1,5-b]pyridazine",C1=CC=C(C=C1)S(=O)C2=NN3C(=NN=N3)C=C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.12,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,245.267,0.686,0,6
"1180676 -- 3-Chloro-1-(3,4-dichlorophenyl)-4-(4-methylpiperazin-1-yl)pyrrole-2,5-dione",CN1CCN(CC1)C2=C(C(=O)N(C2=O)C3=CC(=C(C=C3)Cl)Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.23,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,374.655,2.5644,0,4
1570 -- Pyrithione,C1=CC(=S)N(C=C1)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.05,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,127.168,1.45489,1,3
"CID 390892 -- Acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;hydrochloride",C[N+]1=C2C=C(C=CC2=CC3=C1C=C(C=C3)N)N.C1=CC(=CC2=NC3=C(C=CC(=C3)N)C=C21)N.Cl.[Cl-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.93,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,505.453,1.9601,4,5
7464118 -- Heclin,CCC1=CC=C(O1)/C=C/C(=O)NC2=CC=C(C=C2)C(=O)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.95,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,283.327,3.6965,1,3
521106 -- Bis(2-hydroxy-1-naphthyl) disulfide,C1=CC=C2C(=C1)C=CC(=C2SSC3=C(C=CC4=CC=CC=C43)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.51,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,350.464,6.2036,2,4
16219298 -- (-)-Eseroline fumarate,C[C@@]12CCN(C1N(C3=C2C=C(C=C3)O)C)C.C(=C\C(=O)O)\C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.372,1.4731,3,5
16219298 -- (-)-Eseroline fumarate,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)O)C)C.C(=C/C(=O)O)\C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.372,1.4731,3,5
16219298 -- (-)-Eseroline fumarate,CC12CCN(C1N(C3=C2C=C(C=C3)O)C)C.C(=CC(=O)O)C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.372,1.4731,3,5
16219298 -- (-)-Eseroline fumarate,C[C@]12CCN(C1N(C3=C2C=C(C=C3)O)C)C.C(=C/C(=O)O)\C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.372,1.4731,3,5
5281800 -- Acteoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.54,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,624.592,-1.0159,9,15
73111 -- Sennoside A,C1=CC2=C(C(=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)C4=C([C@@H]2[C@@H]5C6=C(C(=CC=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.59,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,862.746,-1.0956,12,18
2907339  -- 7-[(3-Ethoxy-4-methoxyphenyl)-[(4-methylpyridin-2-yl)amino]methyl]quinolin-8-ol,CCOC1=C(C=CC(=C1)C(C2=C(C3=C(C=CC=N3)C=C2)O)NC4=NC=CC(=C4)C)OC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.27,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,415.493,5.25262,2,6
697993  -- 2-Mercaptobenzothiazole,C1=CC=C2C(=C1)NC(=S)S2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.74,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,167.258,2.95889,1,2
11957519  -- Dihydrexidine hydrochloride,C1CC2=CC(=C(C=C2[C@@H]3[C@@H]1NCC4=CC=CC=C34)O)O.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.05,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,303.789,3.0695,3,3
441244  -- Silver sulfadiazine,C1=CN=C(N=C1)[N-]S(=O)(=O)C2=CC=C(C=C2)N.[Ag+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.75,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,357.143,1.4504,1,5
441244  -- Silver sulfadiazine,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N.[Ag],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.75,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,358.151,0.8571,2,5
441244  -- Silver sulfadiazine,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.75,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,250.283,0.8596,2,5
3938248  -- 2-Amino-6-mercaptopurine riboside,C1=NC2=C(N1C3C(C(C(O3)CO)O)O)NC(=NC2=S)N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.08,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,299.312,-1.31741,5,9
54747  -- Caracemide,CC(=O)N(C(=O)NC)OC(=O)NC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.33,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,189.171,-0.5547,2,4
"4124851  -- 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione",CN1C(=O)N(C(=O)S1)CC2=CC=CC=C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,222.269,0.6568,0,5
5455  -- Thiram,CN(C)C(=S)SSC(=S)N(C)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.05,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,240.444,2.0608,0,4
123810  -- 15-(4-Iodophenyl)pentadecanoic acid,C1=CC(=CC=C1CCCCCCCCCCCCCCC(=O)O)I,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.25,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.397,6.9896,1,1
10224714  -- (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol,CC[C@H](CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=C(C=C3)C4=CC=CC=N4,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.84,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,431.544,4.2641,3,8
"8447  -- 2,2'-Dithiobisbenzothiazole",C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.16,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,332.5,5.7054,0,6
"2747117  -- 4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one",C1COC2=C(O1)C=CC(=C2)N3C(=O)NN=C3SC4=NC=C(S4)[N+](=O)[O-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.3,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,379.379,1.8477,1,10
7347  -- Tetramethylthiuram monosulfide,CN(C)C(=S)SC(=S)N(C)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.94,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,208.377,1.4126,0,3
2327  -- Benserazide,C1=CC(=C(C(=C1CNNC(=O)C(CO)N)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,257.246,-1.7562,7,7
636411  -- Tenatoprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=CC(=N3)OC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.97,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,346.412,2.29474,1,6
"CID 23384  -- 6-Bromonaphthalene-1,2-dione",C1=CC2=C(C=CC(=O)C2=O)C=C1Br,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.04,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,237.052,2.2277,0,2
"23384  -- 6-Bromonaphthalene-1,2-dione",C1=CC2=C(C=CC(=O)C2=O)C=C1Br,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.16,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,237.052,2.2277,0,2
"665449  -- tert-butyl N-[2-[5-[(2,4-dichlorophenyl)methylsulfonyl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate",CC(C)(C)OC(=O)NCCC1=NN=C(O1)S(=O)(=O)CC2=C(C=C(C=C2)Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.22,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,436.317,3.4175,1,7
2577  -- Carmofur,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.16,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,257.265,0.8137,2,4
"313619  -- 7-Nitro-4-(1-oxidopyridin-1-ium-2-yl)sulfanyl-2,1,3-benzoxadiazole",C1=CC=[N+](C(=C1)SC2=CC=C(C3=NON=C23)[N+](=O)[O-])[O-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.1,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,290.26,1.9156,0,7
3117  -- Disulfiram,CCN(CC)C(=S)SSC(=S)N(CC)CC,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.22,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,296.552,3.6212,0,4
73343  -- Ammonium pyrrolidyldithiocarbamate,C1CCN(C1)C(=S)S.N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.21,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,164.299,1.4589,2,2
9810709  -- Aldoxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
9810709  -- Aldoxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N\NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
9810709  -- Aldoxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2C[C@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
9810709  -- Aldoxorubicin,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)CCCCCN6C(=O)C=CC6=O)CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
9810709  -- Aldoxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
9810709  -- Aldoxorubicin,CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=NNC(=O)CCCCCN6C(=O)C=CC6=O)CO)O)N)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,750.758,0.3898,7,15
2450  -- Bronopol,C(C(CO)([N+](=O)[O-])Br)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,199.988,-0.6611,2,4
"CID 2886035  -- 1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione",CC1=CC(=CC(=C1)N2C(=O)CC(C2=O)SC3=NC=NN3)C,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.17,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,302.359,1.84574,1,5
5281605  -- Baicalein,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.02,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,270.24,2.5768,3,5
4534  -- Nordihydroguaiaretic acid,CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.59,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,302.37,3.5664,4,4
"707055  -- 5-(Phenylamino)-1,3,4-thiadiazole-2(3H)-thione",C1=CC=C(C=C1)NC2=NNC(=S)S2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.39,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,209.299,2.94429,2,4
442514  -- Haematoxylin,C1C2=CC(=C(C=C2[C@H]3[C@@]1(COC4=C3C=CC(=C4O)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.22,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,302.282,1.3205,5,6
135413533  -- TAS-103 free base,CN(C)CCNC1=NC2=C(C=CC(=C2)O)C3=C1C(=O)C4=CC=CC=C43,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.99,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,333.391,3.1253,2,5
"85040  -- 6,6'-Dithiodinicotinic acid",C1=CC(=NC=C1C(=O)O)SSC2=NC=C(C=C2)C(=O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.24,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,308.34,2.6724,2,6
14720269  -- Rabeprazole sodium,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.74,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,381.433,-0.37748,0,5
"682802  -- Methanamine, N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)-",CN=C1N=C(N(S1)C2=CC=CC=C2)C3=CC=CC=C3,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.98,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,267.357,3.1313,0,4
5489012  -- Oxyfedrine hydrochloride,C[C@@H]([C@@H](C1=CC=CC=C1)O)NCCC(=O)C2=CC(=CC=C2)OC.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.35,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,349.858,3.4015,2,4
59599728  -- 2-Hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde,CN1CCN(CC1)C(=O)C2=CC=C(S2)C3=CC4=C(C=C3)C(=C(C=C4)O)C=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.33,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,380.469,3.474,1,5
5281792  -- Rosmarinic acid,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.86,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,360.318,1.7613,5,7
5281792  -- Rosmarinic acid,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.86,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,360.318,1.7613,5,7
12928470  -- SKF 38393 hydrobromide,C1CNCC(C2=CC(=C(C=C21)O)O)C3=CC=CC=C3.Br,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.63,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,336.229,2.9533,3,3
"1510389  -- 2-(2,5-Dimethylphenyl)-6-fluoro-1,2-benzothiazol-3-one",CC1=CC(=C(C=C1)C)N2C(=O)C3=C(S2)C=C(C=C3)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.02,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,273.332,3.80814,0,3
"230748  -- 9,10-Dihydro-9,10[1',2']-benzenoanthracene-1,4-dione",C1=CC=C2C3C4=CC=CC=C4C(C2=C1)C5=C3C(=O)C=CC5=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.24,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,284.314,3.282,0,2
"CID 135403797  -- 2,3,4,6-tetrahydroxy-5H-benzo[7]annulen-5-one",C1=CC2=CC(=C(C(=C2C(=O)C(=C1)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.58,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,220.18,1.0224,4,5
CID 416002  -- 5-Aminoquinolin-8-ol,C1=CC2=C(C=CC(=C2N=C1)O)N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.05,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,160.176,1.5226,2,3
"2725942  -- 6-[Morpholin-4-yl-[4-(trifluoromethyl)phenyl]methyl]-1,3-benzodioxol-5-ol",C1COCCN1C(C2=CC=C(C=C2)C(F)(F)F)C3=CC4=C(C=C3O)OCO4,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.54,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,381.35,3.5613,1,5
5281672  -- Myricetin,C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.22,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,318.237,1.6936,6,8
5281672  -- Myricetin,C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.4,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,318.237,1.6936,6,8
40399  -- Exifone,C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.38,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,278.216,1.1512,6,7
47318  -- Oltipraz,CC1=C(SSC1=S)C2=NC=CN=C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.21,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.351,3.30451,0,5
47318  -- Oltipraz,CC1=C(SSC1=S)C2=NC=CN=C2,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.62,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,226.351,3.30451,0,5
5388906  -- Bedaquiline,CN(C)CC[C@@](C1=CC=CC2=CC=CC=C21)([C@H](C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.36,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,555.516,7.1305,1,4
11313622  -- Tideglusib,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.08,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.4,3.2622,0,5
11313622  -- Tideglusib,C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.15,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,334.4,3.2622,0,5
"6918567  -- N-methyl-N-(2-methylphenyl)-3-nitro-4-(1,3-thiazol-2-ylsulfinyl)benzamide",CC1=CC=CC=C1N(C)C(=O)C2=CC(=C(C=C2)S(=O)C3=NC=CS3)[N+](=O)[O-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.87,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,401.469,3.80302,0,6
439647  -- Tosylphenylalanyl chloromethyl ketone,CC1=CC=C(C=C1)S(=O)(=O)N[C@@H](CC2=CC=CC=C2)C(=O)CCl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.37,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,351.855,2.69252,1,3
"1074953  -- 3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione",C1COCCN1C2=C(C(=O)N(C2=O)C3=CC(=C(C=C3)Cl)Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.53,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,361.612,2.6492,0,4
"1074953  -- 3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione",C1COCCN1C2=C(C(=O)N(C2=O)C3=CC(=C(C=C3)Cl)Cl)Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,361.612,2.6492,0,4
3883  -- Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.39,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,369.368,3.51522,1,4
3883  -- Lansoprazole,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.6,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,369.368,3.51522,1,4
"11393719  -- N-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[5,4-d]pyridin-7-yl]methyl]piperidin-4-amine",CCN1C2=C(C=NC=C2CNC3CCNCC3)N=C1C4=NON=C4N,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.07,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,342.407,0.925,3,9
9410  -- Apomorphine hydrochloride,CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,303.789,3.2717,2,3
9410  -- Apomorphine hydrochloride,CN1CCC2=C3C1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,303.789,3.2717,2,3
9410  -- Apomorphine hydrochloride,CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,267.328,2.8499,2,3
9410  -- Apomorphine hydrochloride,CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.O.Cl,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,321.804,2.447,2,3
9410  -- Apomorphine hydrochloride,CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.[Cl-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,302.781,-0.1461,2,3
9410  -- Apomorphine hydrochloride,[H+].[H+].CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.CN1CCC2=C3[C@H]1CC4=C(C3=CC=C2)C(=C(C=C4)O)O.O.[Cl-].[Cl-],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.52,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,625.593,-0.8919,4,6
2724354  -- Succimer,[C@@H]([C@@H](C(=O)O)S)(C(=O)O)S,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.72,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,182.222,-0.2476,4,4
"227681  -- (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl propionate",CCC(=O)OCN1C(=O)C=CC1=O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.29,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,183.163,-0.1779,0,4
161557  -- Dihydromyricetin,C1=C(C=C(C(=C1O)O)O)[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.18,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,320.253,0.8919,6,8
3005837  -- Zinc pyridinethione,C1=CC(=S)N(C=C1)[O-].C1=CC(=S)N(C=C1)[O-].[Zn+2],SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.46,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,317.71,3.12448,0,6
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H]([C@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)C=CC2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H](C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H](C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@@H]([C@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)/C=C/C2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C\C2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1CC(C(=O)O)OC(=O)/C=C\C2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
11629084  -- Salvianolic acid B,C1=CC(=C(C=C1C[C@H](C(=O)O)OC(=O)/C=C/C2=C3[C@H]([C@@H](OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)O[C@@H](CC5=CC(=C(C=C5)O)O)C(=O)O)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.42,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,718.62,3.3345,9,14
"152256  -- 2,4,6-Triiodoresorcinol",C1=C(C(=C(C(=C1I)O)I)O)I,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.33,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,487.8,2.9116,2,2
"135398520  -- (E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide",C1=C(C=C(C(=C1O)O)O)CNC(=S)C=CC2=CC(=C(C(=C2)Br)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.48,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,412.261,3.1075,6,6
"135398520  -- (E)-3-(3-Bromo-4,5-dihydroxyphenyl)-N-(3,4,5-trihydroxybenzyl)prop-2-enethioamide",C1=C(C=C(C(=C1O)O)O)CNC(=S)/C=C/C2=CC(=C(C(=C2)Br)O)O,SARS-CoV-2 3CL-Pro protease inhibition IC50 determined by FRET kind of response from peptide substrate,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.48,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,412.261,3.1075,6,6
146672237  -- SARS-CoV MPro-IN-1,C1CNC(=O)[C@@H]1C[C@@H](C=O)NC(=O)[C@H](CC2=CC(=CC=C2)F)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of recombinant SARS CoV-2 main protease expressed in Escherichia coli using MCA-AVLQ SGFR-Lys (Dnp)-Lys-NH2 as substrate by FRET based assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.04,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
146672237  -- SARS-CoV MPro-IN-1,C1CNC(=O)C1CC(C=O)NC(=O)C(CC2=CC(=CC=C2)F)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of recombinant SARS CoV-2 main protease expressed in Escherichia coli using MCA-AVLQ SGFR-Lys (Dnp)-Lys-NH2 as substrate by FRET based assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.04,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
11561899  -- B5R5IQ1D64,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(=O)CO)NC(=O)C2=CC3=C(N2)C=CC=C3OC,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.008,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,472.542,0.8934,5,6
11561899  -- B5R5IQ1D64,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)CO)NC(=O)C2=CC3=C(N2)C=CC=C3OC,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.008,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,472.542,0.8934,5,6
134306185  -- Cbz-Leu-Leu-Ala(((S)-2-oxopyrrolidin-3-yl))-Unk,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(=O)C(=O)NC(C)C)NC(=O)C(CC(C)C)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.065,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,601.745,1.9631,5,7
134306185  -- Cbz-Leu-Leu-Ala(((S)-2-oxopyrrolidin-3-yl))-Unk,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)C(=O)NC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.065,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,601.745,1.9631,5,7
71508882  -- peptidomimetic coronavirus 3CLpro inhibitors 2i,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(=O)C2=NC3=CC=CC=C3S2)NC(=O)C(C(C)C)NC(=O)OCC4=CC=CC=C4,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.094,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,635.787,3.9719,4,8
71508882  -- peptidomimetic coronavirus 3CLpro inhibitors 2i,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)C2=NC3=CC=CC=C3S2)NC(=O)[C@H](C(C)C)NC(=O)OCC4=CC=CC=C4,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.094,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,635.787,3.9719,4,8
146672237  -- SARS-CoV MPro-IN-1,C1CNC(=O)C1CC(C=O)NC(=O)C(CC2=CC(=CC=C2)F)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.023,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
146672237  -- SARS-CoV MPro-IN-1,C1CNC(=O)[C@@H]1C[C@@H](C=O)NC(=O)[C@H](CC2=CC(=CC=C2)F)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.023,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,464.497,1.858,4,4
"118737648  -- (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid",CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)O)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.034,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
"11444522  -- ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate",CCOC(=O)C=CC(CC1CCNC1=O)NC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.286,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,572.703,2.5986,4,7
"11444522  -- ethyl (2E,4S)-4-[(2S)-2-[(2S)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]-4-methylpentanamido]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate",CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.286,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,572.703,2.5986,4,7
141697527  -- Benzyl ((S)-4-methyl-1-oxo-1-(((S)-1-oxo-3-((S)-2-oxopyrrolidin-3-yl)propan-2-yl)amino)pentan-2-yl)carbamate,CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C=O)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.042,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,403.479,1.5374,3,5
9868928  -- Z-LL-Nva-CHO,CCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.14,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,461.603,3.3422,3,5
462382  -- Z-Leu-leu-leu-al,CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.9,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,475.63,3.5882,3,5
"164622832  -- (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(2,2-dimethylpropanoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide",CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.672,1.7758,3,5
"164622832  -- (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(2,2-dimethylpropanoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide",CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.13,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.672,1.7758,3,5
"118737648  -- (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid",CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(O)S(=O)(=O)O)NC(=O)OCC2=CC=CC=C2,Inhibition of SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQ/SGFRKME(Edans) substrate and measured after 1 hr by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.03,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
145343771  -- Unii-T5UX5skk2S,C1CCC(CC1)C[C@@H](C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of recombinant SARS CoV-2 main protease expressed in Escherichia coli using MCA-AVLQ SGFR-Lys (Dnp)-Lys-NH2 as substrate by FRET based assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.053,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
145343771  -- Unii-T5UX5skk2S,C1CCC(CC1)C[C@@H](C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of recombinant SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of DABCYL-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu-EDANS substrate and measured after 30 mins by micro,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.031,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
"118737648  -- (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid",CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)O)NC(=O)OCC2=CC=CC=C2,Inhibition of recombinant SARS-CoV-2 Main protease expressed in Escherichia coli BL21 (DE3) preincubated for 30 mins followed by addition of DABCYL-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu-EDANS substrate and measured after 30 mins by micro,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.031,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,485.559,0.5447,5,7
73364  -- Calpeptin,CCCCC(C=O)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1,Inhibition of SARS-CoV-2 3CL (3264 to 3569 residues) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQSGFRKME(Edans) substrate and measured after 1 hr by flourescence based plate reader assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.81,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,362.47,3.2014,2,4
73364  -- Calpeptin,CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1,Inhibition of SARS-CoV-2 3CL (3264 to 3569 residues) preincubated for 30 mins followed by addition of Dabcyl-KTSAVLQSGFRKME(Edans) substrate and measured after 1 hr by flourescence based plate reader assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.81,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,362.47,3.2014,2,4
11844348  -- Cbz-Thr(tBu)-Cha-Ala(((S)-2-oxopyrrolidin-3-yl))-al,CC(C(C(=O)NC(CC1CCCCC1)C(=O)NC(CC2CCNC2=O)C=O)NC(=O)OCC3=CC=CC=C3)OC(C)(C)C,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.009,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.757,3.1501,4,7
11844348  -- Cbz-Thr(tBu)-Cha-Ala(((S)-2-oxopyrrolidin-3-yl))-al,C[C@H]([C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O)NC(=O)OCC3=CC=CC=C3)OC(C)(C)C,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.009,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,600.757,3.1501,4,7
145343771  -- Unii-T5UX5skk2S,C1CCC(CC1)CC(C(=O)NC(CC2CCNC2=O)C=O)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.014,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
145343771  -- Unii-T5UX5skk2S,C1CCC(CC1)C[C@@H](C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O)NC(=O)C3=CC4=CC=CC=C4N3,Inhibition of SARS-CoV-2 3CLpro preincubated for 30 mins followed by addition of (Dabcyl)KTSAVLQSGFRKM(Glu) peptide substrate and measured after 1.5 hrs by FRET assay,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.014,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,452.555,2.4466,4,4
"135936503  -- 4-{[(2-{[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(4-hydroxy-3-methoxyphenyl)methyl]amino}-4-oxo-4,5-dihydro-1,3-thiazol-5-yl)acetyl]amino}benzoic acid",COC1=C(C=CC(=C1)C(C2=C(NC(=O)NC2=O)O)N=C3NC(=O)C(S3)CC(=O)NC4=CC=C(C=C4)C(=O)O)O,Inhibition of SARS-CoV-2 papain-like protease,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.085,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,555.525,0.887,7,10
"135699256  -- N'-[(E)-(2-hydroxyphenyl)methylideneamino]-4-[[[4-[(E)-N'-[(E)-(2-hydroxyphenyl)methylideneamino]carbamimidoyl]-1,2,5-oxadiazol-3-yl]amino]methylamino]-1,2,5-oxadiazole-3-carboximidamide",C1=CC=C(C(=C1)C=NN=C(C2=NON=C2NCNC3=NON=C3C(=NN=CC4=CC=CC=C4O)N)N)O,Inhibition of SARS-CoV-2 papain-like protease,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.063,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.471,0.8241,6,14
"135699256  -- N'-[(E)-(2-hydroxyphenyl)methylideneamino]-4-[[[4-[(E)-N'-[(E)-(2-hydroxyphenyl)methylideneamino]carbamimidoyl]-1,2,5-oxadiazol-3-yl]amino]methylamino]-1,2,5-oxadiazole-3-carboximidamide",C1=CC=C(C(=C1)/C=N/N=C(/N)\C2=NON=C2NCNC3=NON=C3/C(=N\N=C\C4=CC=CC=C4O)/N)O,Inhibition of SARS-CoV-2 main protease,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.11,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,504.471,0.8241,6,14
"135936503  -- 4-{[(2-{[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(4-hydroxy-3-methoxyphenyl)methyl]amino}-4-oxo-4,5-dihydro-1,3-thiazol-5-yl)acetyl]amino}benzoic acid",COC1=C(C=CC(=C1)C(C2=C(NC(=O)NC2=O)O)N=C3NC(=O)C(S3)CC(=O)NC4=CC=C(C=C4)C(=O)O)O,Inhibition of SARS-CoV-2 main protease,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,0.45,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,555.525,0.887,7,10
164626388  -- N-benzyl-2-(1H-indol-3-ylsulfanyl)-N-methylacetamide,CN(CC1=CC=CC=C1)C(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.55,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,310.422,3.9186,1,2
"164618518  -- N,N-dibenzyl-2-[(4-bromo-1H-indol-3-yl)sulfanyl]acetamide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=O)CSC3=CNC4=C3C(=CC=C4)Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.76,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,465.416,6.2515,1,2
"164625229  -- N,N-dibenzyl-2-(1H-indol-3-ylsulfanyl)acetamide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=O)CSC3=CNC4=CC=CC=C43,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.35,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,386.52,5.489,1,2
121304016  -- Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.19,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,602.585,2.31218,4,13
164609837  -- 2-[(4-bromo-1H-indol-3-yl)sulfanyl]-N-[(2-ethoxyphenyl)methyl]-N-methoxyacetamide,CCOC1=CC=CC=C1CN(C(=O)CSC2=CNC3=C2C(=CC=C3)Br)OC,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.11,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,449.37,5.0114,1,4
164609074  -- N-[(2-methoxyphenyl)methyl]-2-[(7-phenyl-1H-indol-3-yl)sulfanyl]acetamide,COC1=CC=CC=C1CNC(=O)CSC2=CNC3=C2C=CC=C3C4=CC=CC=C4,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.65,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,402.519,5.252,2,3
164615643  -- 2-(1H-indol-3-ylsulfanyl)-N-[(2-methoxyphenyl)methyl]-N-methylacetamide,CN(CC1=CC=CC=C1OC)C(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.64,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,340.448,3.9272,1,3
4652615  -- N-benzyl-2-(1H-indol-3-ylsulfanyl)acetamide,C1=CC=C(C=C1)CNC(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,6.81,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,296.395,3.5764,2,2
"164626780  -- 2-[(5-bromo-1H-indol-3-yl)sulfanyl]-N-[(3,4-dichlorophenyl)methyl]acetamide",C1=CC(=C(C=C1CNC(=O)CSC2=CNC3=C2C=C(C=C3)Br)Cl)Cl,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,9.77,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.181,5.6457,2,2
"164626986  -- N,N-dibenzyl-2-[(7-bromo-1H-indol-3-yl)sulfanyl]acetamide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=O)CSC3=CNC4=C3C=CC=C4Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.08,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,465.416,6.2515,1,2
164625792  -- 2-(1H-indol-3-ylsulfanyl)-N-[(1R)-1-phenylethyl]acetamide,CC(C1=CC=CC=C1)NC(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,6.68,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,310.422,4.1374,2,2
164625792  -- 2-(1H-indol-3-ylsulfanyl)-N-[(1R)-1-phenylethyl]acetamide,C[C@H](C1=CC=CC=C1)NC(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,6.68,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,310.422,4.1374,2,2
164612967  -- N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-(1H-indol-3-ylsulfanyl)acetamide,CN(C)CCOC1=CC=C(C=C1)CNC(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,9.08,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,383.517,3.5168,2,4
164614701  -- 2-[(4-bromo-1H-indol-3-yl)sulfanyl]-N-[(2-methoxyphenyl)methyl]acetamide,COC1=CC=CC=C1CNC(=O)CSC2=CNC3=C2C(=CC=C3)Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,8.71,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,405.317,4.3475,2,3
"164621676  -- 2-[(7-bromo-1H-indol-3-yl)sulfanyl]-N-[(3,4-dichlorophenyl)methyl]acetamide",C1=CC2=C(C(=C1)Br)NC=C2SCC(=O)NCC3=CC(=C(C=C3)Cl)Cl,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.55,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.181,5.6457,2,2
164614965  -- N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-2-(1-methylindol-3-yl)sulfanylacetamide,CN1C=C(C2=CC=CC=C21)SCC(=O)NCC3=CC=C(C=C3)OCCN(C)C,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,8.91,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,397.544,3.5272,1,5
164629085  -- 2-[(7-bromo-1H-indol-3-yl)sulfanyl]-N-[(2-methoxyphenyl)methyl]acetamide,COC1=CC=CC=C1CNC(=O)CSC2=CNC3=C2C=CC=C3Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.08,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,405.317,4.3475,2,3
"164625230  -- 2-[(4-bromo-1H-indol-3-yl)sulfanyl]-N-[(3,4-dichlorophenyl)methyl]acetamide",C1=CC2=C(C(=C1)Br)C(=CN2)SCC(=O)NCC3=CC(=C(C=C3)Cl)Cl,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.21,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.181,5.6457,2,2
164620091  -- N-benzyl-2-[(4-bromo-1H-indol-3-yl)sulfanyl]-N-methylacetamide,CN(CC1=CC=CC=C1)C(=O)CSC2=CNC3=C2C(=CC=C3)Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.73,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,389.318,4.6811,1,2
"164612005  -- N-[(3,4-dichlorophenyl)methyl]-2-(1-methylindol-3-yl)sulfanylacetamide",CN1C=C(C2=CC=CC=C21)SCC(=O)NCC3=CC(=C(C=C3)Cl)Cl,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.5,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,379.312,4.8936,1,3
164611183  -- N-[(2-methoxyphenyl)methyl]-2-(1-methylindol-3-yl)sulfanylacetamide,CN1C=C(C2=CC=CC=C21)SCC(=O)NCC3=CC=CC=C3OC,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,9.82,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,340.448,3.5954,1,4
"164608947  -- 2-[(6-bromo-1H-indol-3-yl)sulfanyl]-N-[(3,4-dichlorophenyl)methyl]acetamide",C1=CC(=C(C=C1CNC(=O)CSC2=CNC3=C2C=CC(=C3)Br)Cl)Cl,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,8.71,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,444.181,5.6457,2,2
164619177  -- 2-(1H-indol-3-ylsulfanyl)-N-[[4-(trifluoromethyl)phenyl]methyl]acetamide,C1=CC=C2C(=C1)C(=CN2)SCC(=O)NCC3=CC=C(C=C3)C(F)(F)F,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,7.94,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,364.392,4.5952,2,2
121304016  -- Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.56,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,602.585,2.31218,4,13
164626388  -- N-benzyl-2-(1H-indol-3-ylsulfanyl)-N-methylacetamide,CN(CC1=CC=CC=C1)C(=O)CSC2=CNC3=CC=CC=C32,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,5.37,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,310.422,3.9186,1,2
"164625229  -- N,N-dibenzyl-2-(1H-indol-3-ylsulfanyl)acetamide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=O)CSC3=CNC4=CC=CC=C43,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,4.01,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,386.52,5.489,1,2
121304016  -- Remdesivir,CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.11,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,602.585,2.31218,4,13
164609837  -- 2-[(4-bromo-1H-indol-3-yl)sulfanyl]-N-[(2-ethoxyphenyl)methyl]-N-methoxyacetamide,CCOC1=CC=CC=C1CN(C(=O)CSC2=CNC3=C2C(=CC=C3)Br)OC,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,1.89,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,449.37,5.0114,1,4
"164618518  -- N,N-dibenzyl-2-[(4-bromo-1H-indol-3-yl)sulfanyl]acetamide",C1=CC=C(C=C1)CN(CC2=CC=CC=C2)C(=O)CSC3=CNC4=C3C(=CC=C4)Br,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,3.85,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,465.416,6.2515,1,2
164609074  -- N-[(2-methoxyphenyl)methyl]-2-[(7-phenyl-1H-indol-3-yl)sulfanyl]acetamide,COC1=CC=CC=C1CNC(=O)CSC2=CNC3=C2C=CC=C3C4=CC=CC=C4,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp10,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),active,2.18,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,1,402.519,5.252,2,3
"164621889  -- (5R,8S,11S,14S,17S,20S)-17-(3-amino-3-oxopropyl)-14-(2-methylpropyl)-6,9,12,15,18-pentaoxo-8,11-di(propan-2-yl)-3-thia-7,10,13,16,19,25,27-heptazatricyclo[20.3.1.12,5]heptacosa-1(25),2(27),22(26),23-tetraene-20-carboxamide",CC(C)CC1C(=O)NC(C(=O)NC(CC2=CC(=NC=C2)C3=NC(CS3)C(=O)NC(C(=O)NC(C(=O)N1)C(C)C)C(C)C)C(=O)N)CCC(=O)N,Binding affinity to SARS CoV-2 15N/2H-labeled main protease assessed as chemical pertubations at 100 uM by 15HSQC-NMR spectrum analysis,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),inactive,,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,715.878,-0.9674,7,10
"164621889  -- (5R,8S,11S,14S,17S,20S)-17-(3-amino-3-oxopropyl)-14-(2-methylpropyl)-6,9,12,15,18-pentaoxo-8,11-di(propan-2-yl)-3-thia-7,10,13,16,19,25,27-heptazatricyclo[20.3.1.12,5]heptacosa-1(25),2(27),22(26),23-tetraene-20-carboxamide",CC(C)C[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC2=CC(=NC=C2)C3=N[C@@H](CS3)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)C(C)C)C(=O)N)CCC(=O)N,Binding affinity to SARS CoV-2 15N/2H-labeled main protease assessed as chemical pertubations at 100 uM by 15HSQC-NMR spectrum analysis,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),inactive,,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,715.878,-0.9674,7,10
"164624927  -- (5R,8S,11S,14S,17S,20S,23S,26S)-20-(3-amino-3-oxopropyl)-8,11,23-trimethyl-17-(2-methylpropyl)-6,9,12,15,18,21,24-heptaoxo-14-propan-2-yl-3-thia-7,10,13,16,19,22,25,31,33-nonazatricyclo[26.3.1.12,5]tritriaconta-1(31),2(33),28(32),29-tetraene-26-carboxamide",CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CC2=CC(=NC=C2)C3=NC(CS3)C(=O)NC(C(=O)N1)C)C(=O)N)C)CCC(=O)N)CC(C)C)C(C)C,Binding affinity to SARS CoV-2 15N/2H-labeled main protease assessed as chemical pertubations at 100 uM by 15HSQC-NMR spectrum analysis,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),inactive,,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,829.982,-2.5941,9,12
"164624927  -- (5R,8S,11S,14S,17S,20S,23S,26S)-20-(3-amino-3-oxopropyl)-8,11,23-trimethyl-17-(2-methylpropyl)-6,9,12,15,18,21,24-heptaoxo-14-propan-2-yl-3-thia-7,10,13,16,19,22,25,31,33-nonazatricyclo[26.3.1.12,5]tritriaconta-1(31),2(33),28(32),29-tetraene-26-carboxamide",C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC2=CC(=NC=C2)C3=N[C@@H](CS3)C(=O)N[C@H](C(=O)N1)C)C(=O)N)C)CCC(=O)N)CC(C)C)C(C)C,Binding affinity to SARS CoV-2 15N/2H-labeled main protease assessed as chemical pertubations at 100 uM by 15HSQC-NMR spectrum analysis,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),inactive,,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,829.982,-2.5941,9,12
164628593  -- 2-(1-methylindol-3-yl)sulfanyl-N-[[4-(trifluoromethyl)phenyl]methyl]acetamide,CN1C=C(C2=CC=CC=C21)SCC(=O)NCC3=CC=C(C=C3)C(F)(F)F,Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method,B,Replicase polyprotein 1ab (Severe acute respiratory syndrome coronavirus 2),ORF1ab - ORF1a polyprotein;ORF1ab polyprotein (Severe acute respiratory syndrome coronavirus 2),inactive,,CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,CC(C)C[C@H](C(=O)N[C@H](CC1CCNC1=O)C(O)S(=O)(=O)[O-])NC(=O)OCC2CCC(CC2)(F)F,0,378.419,4.6056,1,3
